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ABSTRACT OF DISSERTATION

CELL AND PROTEIN-BASED SENSING SYSTEMS FOR THE DETECTION OF
ENVIRONMENTALLY AND PHYSIOLOGICALLY RELEVANT MOLECULES
The detection of small molecules in complex sample matrices such as
environmental (surface and ground water, sediment, etc.) and biological (blood,
serum, plasma, etc.) samples is of paramount importance for monitoring the
distribution of environmental pollutants and their patterns of exposure within the
population as well as diagnosing and managing diseases. Biosensors have
demonstrated a singular ability to sensitively and selectively detect analytes in
complex samples without the need for extensive sample preparation and pretreatment. Nature has demonstrated myriad examples of exquisite selectivity in
spite of complexity and we seek to take advantage of that attribute in the
development of novel biosensing systems.
In the work presented here, we have developed both cell- and proteinbased biosensing systems for the detection of hydroxylated polychlorinated
biphenyls (OH-PCBs) and protein-based sensing systems for the detection of
glucose. In the development of a whole-cell sensing system, the regulatory
protein, HbpR, and its associated promoter was used to modulate the expression
of luciferase. Additionally, the effector binding domain of HbpR, HbpR-A, was
isolated and modified with a solvatochromic fluorophore resulting in a proteinbased sensing system. For the detection of glucose, two different glucose
binding proteins were engineered in an effort to tailor their characteristics, such
as binding affinity and thermal stability, to develop a rugged, sensitive proteinbased sensing system. We envision that these biosensing systems will find
applications in the areas of environmental pollutant monitoring and the
management and treatment of diseases such as diabetes.
KEYWORDS: biosesnors, binding proteins, regulatory proteins, protein-based
biosensors, cell-based biosensors
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CHAPTER ONE

INTRODUCTION
Portions reprinted from Turner, et al. Cell-Based Bioluminescent Biosensors
in "Analytical Chemiluminescence and Bioluminescence: Past, Present and
Future", A. Roda, Ed., Royal Society of Chemistry Press, Cambridge, United
Kingdom, 2010

A biosensor is defined as a device that employs biological components
such as proteins, tissues, organelles, nucleic acids, or whole cells to detect a
physicochemical change and produce a measurable signal.

Biosensors are

typically composed of three parts: the biological sensing element, the signal
transducing element, electronic and signal processing components and a display
unit. The transducing element of a biosensor can produce a variety of signal
outputs such as optical, piezoelectric, or electrochemical. Biosensors can be
categorized as either molecular-based (binding proteins, enzymes, antibodies,
aptamers etc.) or cell-based (whole cells, tissues, organisms, etc.). Biosensors
can be designed with certain characteristics, which make them advantageous
over traditional physicochemical analysis methods. These characteristics include
high specificity/selectivity, ease of use, and the ability to provide relevant data
related to the bioavailability of the target analyte in a given sample. Molecularbased biosensors offer the advantage of having generally faster response times
than cell-based ones, although they are typically less rugged due to the often
fragile nature of many isolated biomolecules and they fail to provide information
on the bioavailability of the compound of interest.[1] Additionally, the production
and isolation of biomolecules can be expensive and time-consuming. In contrast,
1

cell-based biosensors are usually more tolerant of extreme conditions, although,
in many cases, they can require longer analysis times.

Cell-based sensing

systems also provide useful information on the bioavailability of the interrogated
analyte and its ability to activate biochemical machinery, which can contribute to
an increased understanding of the toxicity or physiological role of the compound
of interest when this is, for example, an environmental pollutant or a biologically
relevant molecule. As a result of their respective desirable properties, both celland protein- based biosensing systems are finding increasing application in the
fields of environmental and clinical analysis, drug discovery, and toxicology, and
are becoming the focus of much research to improve their characteristics and
engineer them to respond to a greater variety of stimuli and analytes present in
the environment.

DESIGN AND CONSTRUCTION OF BACTERIAL CELL-BASED
BIOLUMINESCENT BIOSENSORS
Bacterial cell-based biosensors share a common basic design and include
similar components. This basic design consists of an intact living cell containing
a DNA sequence, in which the expression of a reporter gene/transducer is under
the control of the promoter of a certain operon. Within this basic design, there
can be much variation depending on the cells being used as a host, the type of
promoter that is utilized (either constitutive or inducible reporter expression), and
the detection strategy that is being employed.

2

As cells grow and are metabolically active, biosensing systems that
employ a constitutive promoter to regulate the expression of the reporter protein,
often present a basal expression of reporter, which produces a measurable
signal even in the absence of the target analyte. This basal signal is reduced if
the cells are subjected to stress as a result of exposure to toxic compounds or
other adverse growing conditions. Thus, this kind of cell-based biosensors that
employ constitutive promoters to regulate the production of a reporter protein can
effectively provide information on the overall toxicity of a sample under
investigation. However, it should be noted that such a system does not provide
any information on the specific nature of the compounds that cause the toxicity to
the cells or the sample.
In contrast, the gene fusion of an inducible promoter to a reporter gene
yields a cell-based biosensing system in which the expression of a reporter
protein occurs only in the presence of a desired condition (Figures 1.1, 1.2).
Therefore, the presence of an analyte of interest activates the expression of a
reporter protein resulting in an increase of the signal produced by the reporter.
An inducible cell-based sensing system such as this is preferred when the goal is
to detect and quantify a particular compound or condition in the sample.
Furthermore, combinations of these genetic operons using different reporter
genes under the control of different promoters can be achieved within a single
organism and yield a single cell-based biosensor capable of responding to
multiple analytes, an advantage when developing multiplexed assays.[2, 3]
Inducible promoters are typically regulated by transcriptional regulatory proteins,
3

Figure 1.1 Schematic of an operon/regulatory protein cell-based biosensor
featuring a negatively regulated operon. In the absence of the analyte, the
regulatory protein is bound to the promoter on the reporter plasmid and prevents
expression of the reporter protein. As the analyte concentration increases, it
binds the regulatory protein, and the analyte-regulatory protein complex
dissociates from the reporter plasmid. This triggers expression of the reporter
protein, and a dose-dependent generation of the signal.

4

Figure 1.2 Schematic of an operon/regulatory protein cell-based biosensor
featuring a positively regulated operon. When an analyte is present, it binds
to the regulatory protein.

This regulatory protein-analyte complex binds the

promoter region on the reporter plasmid, thus triggering the expression of a
reporter protein. This produces a luminescent signal which is dependent on the
concentration of the analyte.

5

a kind of protein that evolved as a response mechanism of an organism to stress.
In general, when an extracellular stimulus/compound acts upon the organism,
these proteins are able to specifically or selectively recognize and bind to this
compound, and subsequently respond by triggering the production of other
proteins involved in defense mechanisms.

These include the production of

protein pumps that control the cellular efflux of the toxic compound(s), metabolic
and synthetic pathway enzymes that degrade them, proteins that can sequester
them, receptor proteins, etc.[1] These inducible-promoter regulatory circuits are
advantageous to the host organism in that they ensure that transcription of their
gene products occurs only when required to increase their survival.

In the

absence of an external stimulus, the regulatory circuit is turned off, no proteins
are expressed from the genes, and the organism can conserve its resources and
energy for other purposes.
In cell-based biosensing systems, recombinant DNA methods are
employed to replace the gene products of the native operon with a reporter gene
that produces a desired signal in response to the presence of a specific
compound recognized by the regulatory protein. Thus, these systems combine
the biospecific recognition afforded by the regulatory proteins with the signal
generation stemming from the reporter gene. An example of the design of one
such system is shown in Figure 1.3 featuring the hbp operon from Pseudomonas
azelaica. The genes hbpC, hbpA, and hbpD of this operon are under the control
of an operator/promoter that is regulated by the product of the gene, hbpR.
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The enzymes, HbpC, HbpA, and HbpD are responsible for the degradation of 2hydroxybiphenyl. A bacterial cell-based biosensor was constructed by replacing
these structural genes with the reporter gene luxAB.

Further study of this

construct demonstrated that it responded to a variety of hydroxylated
polychlorinated biphenyls (OH-PCBs) resulting in an increase in bioluminescence
in a dose-dependent manner.[4]

REGULATION OF REPORTER GENE EXPRESSION
Within the realm of inducible cell-based biosensing systems, the reporter
gene expression may be positively or negatively regulated.

In a negatively

regulated operon (Figure 1.1), a regulatory protein binds to an operator DNA
sequence and prevents the expression of the reporter protein, with this binding
being dependent on the presence or absence of the effector/analyte. In one
instance, the regulatory protein is initially bound to the operator region, thus
repressing the expression of the reporter. As the effector is added, it binds to the
regulatory protein causing it to dissociate from the operator DNA sequence. This
results in an increased expression of the reporter protein. The alternative is that
the effector is required for binding of the regulatory protein to the operator. In
this case, as the effector is added, a regulatory protein-effector complex forms,
which binds to the operator resulting in a decrease in reporter protein expression.
Alternatively, in a positively regulated system (Figure 1.2) the operon
regulation is mediated by a DNA sequence that acts as an “enhancer” of the
system. There are two different mechanisms by which this regulation occurs: In
8

the first possible mechanism, the regulatory protein is bound to the enhancer,
and consequently, produces a high level of initial expression of the reporter
protein. As the concentration of the effector increases, it binds to the regulatory
protein, causing its dissociation from the enhancer and, thus, reducing
expression of the reporter gene. In the second case, the effector is required for
the binding of the regulatory protein to the enhancer sequence. An increase in
the effector concentration leads to the formation of a regulatory protein-effector
complex which, in turn, binds to the enhancer DNA sequence and increases
reporter protein expression.
From an analytical standpoint, it is desirable to have the lowest possible
initial signal and an increasing dose-dependent response as the concentration of
the analyte of interest increases. Thus, the most useful regulatory proteins are
those from very tightly negatively regulated operons where the regulatory protein
is initially bound to the operator and represses reporter protein synthesis.
Accordingly, cell-based biosensing systems based upon these strategies, in
general, afford the lowest limits of detection.

REPORTER GENES AND THEIR ATTRIBUTES
While the sensing element of a cell-based biosensing system determines
the selectivity of its response, the reporter gene largely determines the sensitivity
of the system. In that regard, the variety of reporter genes available is steadily
increasing and each of these reporter genes possesses unique attributes that
must be considered in the design of a biosensing system. The reporter gene of a
9

cell-based sensing system can yield a reporter protein that can generate a
variety of different measurable signals.

This chapter will focus on those

producing an optical/luminescent signal. Optical signals are easily measured,
and an extensive array of instrumentation is available, ranging from very
sophisticated, state-of-the art to less complex, cost-effective hardware depending
on the needs of a particular application.

Additionally, a great variety of

luminescent proteins have been well-characterized.[1, 5]

A summary of the

attributes of a variety of luminescent reporter proteins can be found in table 1.1.
Following is a discussion of each of the types of luminescent reporter proteins
and enzymes capable of generating an optical signal when employing an
appropriate substrate.

A. Luciferases
The term luciferase encompasses a class of enzymes that catalyze a
reaction in which a substrate known generically as a luciferin reacts with oxygen
to produce light. These enzymes offer excellent limits of detection, largely in part
because there is no background luminescence from endogenous activity in other
organisms or from the media and samples in which the measurements are being
taken. The high quantum efficiency of the bioluminescent reactions catalyzed by
these enzymes also contributes to the low detection limits that they afford. Given
that luciferase emits light via a biochemical reaction, there is no need for an
excitation

source,

making

the

instrumentation

needed

for

measuring

bioluminescence simple and cost-effective. These are clear advantages of

10

Table 1.1 Common Reporter Proteins and their Characteristics.
Reporter Protein
[reaction catalyzed]
Detection Method
Bacterial Luciferase
[FMNH2 + R-CHO + O2 
FMN + R-COOH + H2O + hv (490
nm)]
Bioluminescence
Firefly Luciferase
[Firefly luciferin + ATP + O2 +
Mg2+ Oxyluciferin + AMP + Pi +
hv (560 nm)
Bioluminescence
Renilla Luciferase
[Renilla coelenterazine + O2
Coelenteramide + CO2 + hv (480
nm)
Bioluminescence
Aequorin
[Jellyfish coelenterazine + O2 +
Ca2+ Coelenteramide + CO2 +
hv (465 nm)
Bioluminescence
Green Fluorescent Protein
[Formation
of
an
internal
chromophore
Excitation/Emission: 395 nm/509
nm]
Fluorescence
β-Galactosidase
[Hydrolysis of β-Galactosides]
Chemiluminescence
Fluorescence
Colorimetric
Electrochemical

Advantages

Disadvantages

High sensitivity. May not
require substrate. No
endogenous activity in
mammalian or bacterial
cells.
No light source
needed.
High sensitivity. Broad
linear
range.
No
endogenous activity in
mammalian or bacterial
cells. Spectral variants
available. No light source
needed.
No endogenous activity in
bacterial or mammalian
cells.
No light source
needed.
Required
Substrate is membrane
permeable
High sensitivity.
No
endogenous activity in
mammalian or bacterial
cells.
No light source
needed.
Autofluorescent.
No
substrate or cofactors
needed.
Spectral
variants available.
No
endogenous activity in
most systems. Stable at
physiological pH.
Sensitive and stable.
Moderate linear range.
Can be used in anaerobic
environment

Heat Labile.
Narrow
linear range. Requires
aerobic environment.
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Requires
substrate.
Requires
aerobic
environment and ATP.
Requires solubilizers for
substrate
permeability
into cells.
Requires substrate and
may require cell lysis.

Requires substrate and
the presence of Ca2+.

Moderate
sensitivity.
Background fluorescence
from some samples may
interfere. Toxic to some
cell types. Formation of
chromophore can be
slow.
Endogenous
activity.
Requires substrate.

luciferases over other luminescent systems such as those based on fluorescence
and therefore, make this family of enzymes great candidates for use as reporters.
Luciferases have been isolated from a number of organisms, which
include fireflies, bacteria, worms, fungi, etc. Commonly used as reporter genes
in bacterial cell-based biosensing systems are those isolated from bacteria
including members of the genera Vibrio, Xenorhabdus, and Photobacterium.[1]
In these organisms, bioluminescence is conferred by the lux operon which is
comprised of luxCDABE gene cassette. Of the five genes in the lux operon, only
lux A and lux B (with the addition of a suitable substrate) are required for
bioluminescence. The products of these two genes form the catalytically active
dimer, which oxidizes a long-chain aliphatic aldehyde (luciferin) and a reduced
flavin mononucleotide (FMNH2) cofactor to the corresponding carboxylic acid and
FMN, respectively.

During this process, an unstable complex containing an

excited oxide bond is formed, which relaxes to the ground state and the
concomitant emission of light at 490 nm.[6]
While the luxAB genes alone, employed as a reporter, are enough to
produce bioluminescence, the addition of a long-chain aldehyde substrate,
usually decanal, is required unless the entire luxCDABE gene cassette is
present. The enzyme products of the remaining genes in the cassette, lux C, lux
D, and lux E provide the aldehyde substrate needed for bioluminescence.
However, it has been noted that the use of luxABalone results in increased
bioluminescence and, consequently, improved sensitivity of measurement in a
biosensing system.[7] This is likely the result of limited substrate production from
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the products of the lux cassette as opposed to the excess of substrate added
when luxAB is used. The design of a cell-based biosensing system using the
luxCDABEis advantageous in the development of simplified assays and
applications to be used in real-time monitoring.

For applications requiring

increased sensitivity or improved control over when the generation of the
bioluminescence signal occurs, the luxAB reporter gene is preferred.
In addition to bacterial luciferases, firefly luciferase has also been wellcharacterized and widely used as a reporter gene. Firefly luciferase is a 62 kDa
monomer that catalyzes the oxidation of a benzothiazolyl-thiazole luciferin to
oxyluciferin in the presence of ATP, oxygen, and Mg2+.

The oxyluciferin

produced is an excited molecule that subsequently relaxes to a ground state
resulting in the emission of light at a maximum wavelength of 550-575 nm.
Firefly luciferase has approximately 10-fold higher quantum yield than bacterial
luciferase, which endows it with a broad dynamic range (7-8 orders of
magnitude).[8, 9] Additionally, mutagenesis of firefly luciferase has resulted in
enzymes that emit light at wavelengths in a wider range of the visible spectrum
allowing for the development of multiplexed analysis.[10] Examples of these
include red-shifted, thermostable variants of luciferase from Photinuspyralis.[11]
However, the need for the addition of a substrate and the requirement for ATP
can, in some cases, limit the application of firefly luciferase.
Another luciferase well-studied as a bioreporter was isolated from the
marine organism Renilla reniformis, a species of sea pansy. Renilla luciferase is
a 31 kDa monomeric enzyme that catalyzes the oxidation of coelenterazine and
13

results in the emission of light at 480 nm.[12] The sensitivity and dynamic range
of Renilla luciferase is similar to that of firefly luciferase; however, Renilla
luciferase is not as widely used as a bioreporter.[5, 13] In applications where
multiplexing or a dual-reporter based system is desirable this luciferase is
sometimes used along-side firefly luciferase as they have distinctwavelengths of
emission. However, the need for substrate addition and cell lysis make using
either firefly or Renilla luciferases less appealing than bacterial luciferase since
increased cost, time, and error is introduced as a result.
Luciferases from other organisms have been successfully used as
bioreporters in cell based sensing systems. In work by Wu et al., a dual-reporter
system was constructed by transforming NIH 3T3 fibroblast cells with a plasmid
containing Cypridina luciferase (CLuc) fused to a target gene and a plasmid
containing Gaussia luciferase (GLuc) as a control plasmid to monitor gene
expression in these cells.[14] Both CLuc and GLuc are secreted into the growing
medium upon expression and emit at different wavelengths (460 nm and 480 nm,
respectively), allowing for simultaneous measurement without cell lysis.
The variety of luciferases is increasing as novel proteins are being
identified and integrated as reporters into cell-based sensing systems.
example,

the

recently

characterized

luciferases

from

the

For

organisms

Luciolaitalica[15]and Phrixothrixhirtus[16] are expanding the palette of emission
wavelengths available when selecting reporter proteins.

Two other novel

luciferases from the marine copepod, Metridiapacifica, are thermostable
bioluminescent proteins with distinct emission kinetics and are efficiently
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secreted into culture medium upon expression as a result of the presence of an
N-terminal signal peptide.[17]

Because these are secreted into the culture

medium, they could be incorporated into a cell-based sensing system and
continuously monitored in a portion of culture medium independent of cell lysis.

B. Aequorin
Aequorin is a 22 kDa photoprotein native of the marine jellyfish Aequorea
victoria. The emission of bioluminescence by aequorin is different from that of
the luciferases, including Renilla luciferase.

Aequorin needs an organic

imidopyrazine substrate, coelenterazine, and the presence of Ca2+ for emission
of bioluminescence. Coelenterazine resides within a hydrophobic pocket within
the structure of the protein, while Ca2+ binds to three conserved EF-hand regions
of aequorin. It is the binding of aequorin to Ca2+ that causes the protein to
undergo a conformational change, which causes coelenterazine, in the presence
of molecular oxygen, to go through an excited state from which it relaxes to form
coelenteramide and emit bioluminescence at 460-470 nm.[1] The emission from
aequorin follows flash-type kinetics with an emission from the native protein
lasting about 3 seconds and a quantum yield of 0.15.[18]

Mutagenesis of

aequorin has led to the development and characterization of mutants with tuned
emission lifetimes and altered wavelengths allowing for multiplexing in both time
and spatial (wavelength) domains.[19]

While aequorin has found some

application in cell-based biosensing systems, its use has been somewhat limited,
due mostly to its sensitivity to the presence of calcium ions and the need for the
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addition of a substrate. In spite of these limitations, aequorin has been employed
in high-throughput screening assays where its sensitivity to calcium is imperative
in the study of G-protein coupled receptors and in screening compounds that act
as their agonists or antagonists.[20] Also, the detection of specific pathogens,
such as Yersinia pestis and Bacillus anthracis, has been achieved using a
sensing system named CANARY (Cellular Analysis and Notification of Antigen
Risks and Yields).[21] This system is constructed by engineering B cells that
express both aequorin as a bioreporter and membrane-bound antibodies for the
pathogen of interest.

Even when exposed to low levels of pathogen, the

antibodies are capable of recognizing their target. The resulting binding event
triggers an increase in intracellular calcium concentration, which leads to the
subsequent bioluminescence emission by aequorin within seconds.

Novel

relatives of aequorin, such as the photoprotein, clytin, from Clytia gregarium have
been recently characterized and found to be less sensitive to calcium ions.[22]
The availability of spectral variants for multiplexing, exceptional sensitivity (in the
sub-attomole range), and lack of endogenous expression in other organisms
warrants consideration of aequorin as a reporter gene.

C. Green Fluorescent Protein (GFP)
Like aequorin, the green fluorescent protein originates from the jellyfish
Aequorea victoria.

However, unlike the bioluminescent reporter genes

mentioned thus far GFP emits fluorescence. Native GFP is a 238 amino acid
protein possessing a β-barrel structure containing an internal fluorescent
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chromophore. This chromophore is formed from three amino acids (threonine
65, tyrosine 66, glycine 67) in the interior of the protein by cyclization and
oxidation of the tripeptide upon proper protein folding. The exceptional stability
of GFP allows for the accumulation of reporter protein, which is particularly
relevant when used in bacterial cell-based biosensors employing a weak
promoter. GFP does not require a substrate to fluoresce, however as with any
fluorescent reporter, it requires irradiation at its excitation wavelength maximum
of 395 nm, resulting in light emission at a wavelength of 509 nm with a quantum
yield of 0.88.[6, 23] Extensive research has generated a large number of GFP
mutants with altered excitation and emission maxima, stabilities, and signal
intensities.[8, 24, 25] GFP is also tolerated by a variety of cell types, including
mammalian and bacterial cells.

However, because of interference from

background fluorescence in samples, the detection limits afforded by GFP are
not comparable with those of bioluminescent proteins such as the luciferases or
aequorin.[1]

D. β-Galactosidase
The gene product of the lacZ gene from Escherichia coli is βgalactosidase, an enzyme whose biological function is to cleave lactose into
galactose and glucose, although it has been shown that the enzyme may act on
a variety of substrates. Depending on the substrate employed, β-galactosidase
can generate a fluorescent, chemiluminescent, colorimetric, or electrochemical
signal.[25]

For the production of chemiluminescence signals, 1,2-dioxetane
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derivatives are typically used as a substrate. As a reporter gene, lacZ can afford
detection limits as low as 2 fg with a dynamic range of 5-6 orders of
magnitude.[1, 5]

Despite these advantages, the need for the addition of a

substrate and the requirement for cell lysis to make the substrate available to the
enzyme restrict the use of lacZ as a reporter gene for certain specialized
applications.

ADVANTAGES AND LIMITATIONS OF CELL-BASED BIOLUMINESCENT
BIOSENSORS
The continuous discovery of new reporter molecules and recognition
elements by biologists along with advancement in the field of recombinant DNA
broadens the range of types of sensors that can be developed with regard to
selectivity, sensitivity, and parallel analysis.

Moreover, the identification and

investigation of organisms that can be employed and survive in extreme
environments, such as extremophiles and spore-forming microorganisms, should
result in systems that present expanded storage and working conditions and are
more resilient to extreme settings. This improved ruggedness and storage of
cell-based biosensors should make them more amenable to field-portable
environmental and clinical applications.[26]
Uniquely among biosensing systems, cell-based systems can provide
significant information regarding the bioavailability of the compound being
interrogated.[27]

When employing an intact cell in the sensing system, the
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compound being detected must be transported into the cell and activate certain
cellular processes and pathways in order to produce a response. In this regard,
a cell-based sensing system can identify those species, to be transported across
the cell membrane. This information is especially useful in determining relevant
toxicological characteristics of complex mixtures in which some components may
be bioavailable while others may not.

The bioavailable concentration of a

species as detected using a cell-based biosensor is often related to the total
concentration determined by standard physicochemical analysis to better
characterize the sample being analyzed.[28]
While these advantages warrant further study and development of cellbased biosensing systems, there are a number of limitations that must be
overcome before their full potential as an analytical method can be realized.
Inherent to all biological systems is some degree of variability; cell-based
biosensing systems are not immune to this.

This variability can result from

growth of the cells in non-ideal conditions, response to various components in
complex samples, or a number of other unidentified factors. This variation can
contribute to inter- and intra-assay variability. To address this issue, cell-based
systems have been developed that carry a secondary plasmid in which a unique
reporter protein is under the control of a constitutive promoter.[29] This allows
for the response from the analyte-inducible promoter to be normalized with
respect to cell growth and metabolism.
As

previously

mentioned,

cell-based

biosensing

systems

provide

bioavailability information. However, when bacterial whole-cell sensing systems
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are employed, this does not lead to a direct correlation to all relevant
toxicological information as it applies to higher organisms such as humans. This
can be addressed by the development of biosensing systems based on more
complex cell types such as yeast or mammalian cells, thus giving data that is
more applicable to these more complex organisms.

Also, further study of

similarities in biochemical pathways between cell types used in biosensing
systems and cells present in higher organisms may lead to more accurate
extrapolation of relevant toxicological data.
Finally, there can be some degree of instability in the plasmid DNA within
cell-based

sensing

measurement.

systems

resulting

in

decreased

reproducibility

of

This can occur as the cells carrying the exogenous genetic

material reproduce and replicate the plasmid DNA contained within them. While
the rate of error is very low, some mutations can occur. To negate this effect,
plasmid DNA can be integrated into the chromosome of the cells being used,
resulting in increased genetic stability.

APPLICATIONS OF CELL-BASED BIOSENSING SYSTEMS
The distinct properties and advantages discussed previously have allowed
the application of cell-based biosensing systems in different fields. The use of
bioluminescent reporters allows for compact, portable instrumentation due to the
lack of need for an excitation source, a requirement in fluorescence
measurements.

In addition, bioluminescent bioreporters lack the background

signal deriving from fluorescence generated by other components in the sample
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matrix when exciting fluorescent reporters, which contributes to their superior
sensitivity.

Many specific examples can be found throughout the current

literature describing applications in the realm of on-site environmental monitoring,
drug candidate screening, clinical testing, high-throughput screening, etc.
Recent examples of these applications will be highlighted here in more detail.
Additionally, a number of bacterial cell-based biosensing systems are
commercially available; examples of these are shown in table 1.2.
Cell-based biosensors have been engineered that can determine factors
such as general stress, oxidative stress, and genotoxicity. In these constructs, a
reporter gene is placed under the control of a promoter capable of responding in
a dose-dependent manner to one of these stressors. Such systems have been
developed to monitor oxidative stress,[2, 30] protein damage,[30, 31] DNA
damage,[2] among others.
Bacterial cell-based biosensors are commonly used in environmental
monitoring.

Typically, soil and water samples concerning environmental

contamination are complex in nature, containing both naturally occurring and
foreign components. The specificity of the biological recognition element in a
cell-based biosensing system is ideally suited for detecting a desired compound
in a complex mixture. To that end, biosensors have been developed for a variety
of analytes ranging from metals to organic pollutants and representative
examples of these are discussed below.
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Table 1.2 Commercially available bacterial cell-based biosensing systems
Product Name
[Responds To]
Microtox™
[General Toxicity]
Mutatox™
[Mutagenic
Toxicity]

BIOMET™
[Zn, Cd, Cu, Ni,
Pb, Cr, or Hg]
Cellsense™
[Chlorophenols,
other organics]
BioTox™
[General Toxicity]
LumiStox™
[General Toxicity]

Description

Manufacturer

Reference

Inhibition test based
on freeze dried V.
fischeri
Engineered
dark
variant of V. fischeri
recovers
luminescence
restored
upon
exposure
to
mutagenic
compounds

Strategic
Diagnostics,
Inc.
Strategic
Diagnostics,
Inc.

http://www.sdix.com/

Engineered,
metaltolerant
Ralstoniametalliduran
s produces luciferase
in response to metals
Engineered E. coli
produces
amperometric
response to analytes

Vito

Inhibition test based
on freeze dried V.
fischeria tailored for
sediment samples
Inhibition test based
on frozen V. fischeria

Aboatox

http://www.aboatox.com/

Hach Lange

http://www.drlange.com

http://www.sdix.com/

http://wwwa.vito.be/english
/index.htm

Farre, et al.[32]
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There are a number of reports in the current literature regarding cell-based
assays for the detection of inorganic analytes, specifically metals. The design of
these biosensors is based upon the use of regulatory elements from
microorganisms, which natively regulate the expression of genes to confer metal
resistance, to control the expression of a bioreporter instead. Sensing systems
have been developed for a variety of environmentally relevant toxic metals and
metalloids

including

mercury,[33-35]

antimonite/arsenite/arsenate,[36-39]

cadmium,[36, 40, 41] chromate,[42] and aluminum[43] among others.

In

addition, inorganic compounds, such as nitrate, have been detected using cellbased sensing systems.[44] Detection limits as low as femtomolar with analysis
times as short as 30 min have been reported for these species.

Progress

towards the development of a portable biosensing system for the detection of
metals has been achieved by the engineering of a fiber-optic device consisting of
mercury and arsenic sensing bacterial biosensors immobilized on optical
fibers.[45]

Environmentally relevant detection limits were obtained using this

biosensing system: 2.6 µg/L for mercury, 141 µg/L for arsenic(V), and 18 µg/L
for arsenic(III).
Cell-based biosensing systems have been developed for a number of
organic

compounds

including

endocrine

disrupting

compounds

(EDCs),

polychlorinated biphenyls (PCBs) and their metabolites, phenol, catechols,
naphthalene/salicylic acid, benzene/toluene/ethylbenzene/xylene, etc.[5, 46-52]
Many of these compounds are nearly ubiquitous in the environment and pose
negative health effects on many organisms, including humans.
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They share

structural similarities and biological activities with naturally occurring compounds
such as hormones.

Traditional quantification of these compounds from

environmental samples involves extensive sample pretreatment, derivatization,
and extraction prior to detection by a suitable instrumental method. In addition to
environmental samples, it has been demonstrated that a number of varied
analytes can be detected in biological samples such as blood serum, making
whole-cell sensing systems useful in the detection of biomarkers of exposure as
well.[4]
Rather recently, cell-based biosensors have been developed for quorum
sensing

signaling

molecules,

communication system.

the

integral

elements

of

the

bacterial

Quorum sensing is a phenomenon in which certain

bacteria communicate by producing, secreting, sensing and responding to
signaling molecules.

The concentration of these molecules correlates to the

density of the cells.

This cell-to-cell communication allows the organisms to

control the expression of specialized proteins depending on the cell population
size.

Since bacterial processes, such as, production of virulence factors,

formation of biofilms and ability to colonize a certain environment are regulated
by quorum sensing, the detection and quantification of quorum sensing signaling
molecules may be relevant in the investigation of the status of a variety of
diseases that have been linked to bacteria.[53]

Cell-based biosensors have

been developed by placing the expression of a bioreporter under the control of
promoters and associated recognition/regulatory proteins from bacterial quorum
sensing regulatory systems that respond to the presence of quorum sensing
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molecules.[54] Successful use of these sensors has also been demonstrated in
biological samples such as saliva and stool.[55]
Cell-based biosensors also exist for a number of antibiotic compounds.
As the use of antibiotics increases, antibiotic resistance mechanisms in
microorganisms are becoming increasingly widespread.

Antibiotics are also

being found in environmental and food samples; for instance, they have been
detected in chlorinated drinking water at trace levels (down to µg/L levels).[56]
Conventional

methods

to

detect

antibiotics

rely

on

immunoassays,

chromatographic methods, and microbial growth inhibition tests.

Because of

their unique properties, especially the ability to characterize the bioavailability of
an analyte, cell-based biosensors are well-suited for these applications. Such
biosensors have been developed for the detection of antibiotics in various types
of samples such as water and food products,[57]as well as blood and serum.[58]
Cell-based biosensors have been used for the determination of antibiotic activity
on a number of biochemical pathways in tandem with the screening of natural
products for antibiotic activity.

For example, a panel of five gene promoter

regions from the soil bacterium Bacillus subtilis, which have altered mRNA
expression profiles upon antibiotic exposure, were fused to a firefly luciferase
reporter gene.[59] These genes, yorB, yvgS, yheI, ypuA, and fabHB, participate
in biosynthetic pathways such as the synthesis of DNA, RNA, proteins, cell wall,
and fatty acids, respectively. Biosensors based on the use of these genes along
with luciferase have been used in a high-throughput screening mode to
investigate the antibiotic activity of 14,000 natural products. Bacterial cell-based
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biosensors have also been developed to examine the microbicide activity of
some antibacterial polymers.

Luminescence produced by the E. coli strain

O157:H7 modified to express bacterial luciferase via the luxCDABEgene was
monitored upon exposure to polymer compounds to determine bactericidal
properties.[60] Bacterial biosensors also exist for the screening of antimicrobial
activity of compounds in the gas phase that may find use in sterilization
procedures.

To that end, the bioluminescent bacterium Pseudomonas

fluorescens 5RL was immobilized on a 0.2 µm membrane filter and exposed to
varying concentrations of chlorine dioxide gas. In this system, a decrease in
luminescence was correlated to increased antimicrobial activity of the gas.[61]
The detection of other biologically relevant molecules, such as sugars has
also been achieved using a cell-based biosensor approach.

Cell-based

biosensing systems have been developed for a number of sugars by placing the
expression of a reporter gene under the control of a promoter and regulatory
protein responding to the desired sugar.

For example, cells have been

engineered to detect arabinose,[3, 62] glucose,[63] sucrose,[63] and lactose[3,
63]. Multi-analyte detection has been demonstrated with these compounds with
the simultaneous detection of lactose and arabinose using a single biosensing
organism in which two variants of GFP with distinct emissions were used
asreporters for each sugar.[3] Cell-based biosensors are especially useful in the
detection of sugars as they proved certain advantages over conventional
detection methods.

For example, detection of sugars using electrochemical
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methods often suffer from a lack of specificity and those based on spectroscopic
methods require derivatization of sugar with a chromophore substrate.
Applications of bacterial cell-based biosensors can also be found in the
field of molecular biology.

The luxCDABE cassette from Photorhabdus

luminescens was cloned into a pCRII vector and transformed into E. coli. The
resulting cells were then grown with varying concentrations of lytic bacteriophage
T4 at varying temperatures. The bioluminescence was monitored with respect to
time, and as the bacteriophage lysed the bacteria a decrease in bioluminescent
was observed. The results allowed the quantitation of the bacteriophage as well
as determination of its thermal deactivation conditions.[64]
In the field of medicine, genetically engineered bacterial cell-based
biosensors have found applications in imaging in vivo and in vitro.

E. coli

engineered to express GFP in response to quorum sensing molecules, Nacylhomoserine lactones (AHLs), were introduced into mice that had been
infected with Pseudomonas aeruginosa, an opportunistic pathogen that uses
these molecules for intercellular communication.[65]The lung tissue from the
mice was examined by confocal scanning laser microscopy and the pathological
damage observed was correlated to fluorescence measured as a result of
increased AHL levels from bacterial presence. E. coli that migrate preferentially
to tumor tissue, harboring a plasmid containing the luxCDABE cassette, were
injected into mice with CT26 mouse colon cancer and the subsequent bacterial
migration was imaged by detection of bioluminescence from the luciferase
expressing bacteria.[66] The ability to image tumors in vivo in a non-invasive
27

manner is a valuable tool when diagnosing and monitoring the spread of a
different types of cancer, as well as when screening for novel antitumor drugs.
Rather recently, Foucault et al., engineered E. coli to express either bacterial
luciferase or mutants of firefly luciferase that were employed for real-time in vivo
monitoring of infection in mice.[67]The use of bioluminescent bacterial
biosensors in these applications offers a number of advantages, perhaps the
most important being thelower detection limits due to the lack of background
emission associated with similar methods employing fluorescent reporters.

DESIGN STRATEGIES OF PROTEIN-BASED BIOSENSORS
Protein-based biosensors, in contrast to cell-based biosensors, consist of
an isolated protein as the recognition element coupled directly to a signal
transducing element.

The protein employed can be a small-molecule

binding/transport protein, an antibody, a regulatory protein, an enzyme, or a
small peptide fragment derived from functional proteins. The signal output for
these biosensing systems can be electrochemical[68, 69], fluorescent[70],
phosphorescent[71], bioluminescent[72], or piezoelectric[73], etc.

The work

discussed here will focus on those protein-based biosensing systems with an
optical (fluorescence/bioluminescence) signal output. Because isolated proteins
are employed, the assay time is limited only by the timescale of the
recognition/binding event, leading to shorter assay times when compared to cellbased biosensing systems. Additionally, much of the natural variability inherent
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in using metabolically active whole-cells as a sensing element can be reduced or
eliminated when using isolated proteins.
Protein-based sensing systems can be broadly placed in two categories:
genetically-encoded biosensing systems and chemically-modified biosensing
systems (Figure 1.4).

In the genetically encoded approach, the protein is

engineered in such a way that the isolated product contains both the recognition
element and the transducing element without need for further modification. A
typical example of a genetically encoded biosensing system is a fusion of a
ligand binding protein to reporter protein, such as GFP, in which a change in
fluorescence is observed upon ligand binding. Chemically-modified biosensing
systems must be further modified after the protein purification step. Usually, a
sensing protein is modified by covalent attachment of a small reporter molecule.
An example of a chemically-modified protein-based sensor is a ligand binding
protein in which an organic fluorophore is covalently attached to a site on the
protein such that a change in fluorescence can be measured upon ligand
binding.

Following is a more in-depth discussion of each of these types of

sensing systems.

A. Genetically-encoded Biosensing Systems
Genetically encoded protein-based biosensing systems generally consist
of a single protein or a fusion of two or more proteins that, upon purification,
contains both the sensing and transducing elements without the need for further
modification. The most common application for these systems is for in vivo
29

F
Figure
1.4 Comparis
son of ge
enetically-e
encoded and
a
chemiically-modified
p
protein-bas
sed biosensors. In ge
enetically encoded
e
bio
osensors (a
a.), a fusion
n of a
sensing pro
otein (red) to a repo
orter proteiin (green), results in
n a functio
oning
biosensor fo
or a desirred analyte
e (orange) following protein exxpression.

In

contrast, che
emically mo
odified biossensors (b.)) consist of a sensing protein which is
covalently modified
m
a
after
expresssion with an appro
opriate rep
porter mole
ecule
(g
green), which yields a functioning
g biosensorr.

30

imaging for the monitoring of various cellular processes, and there are myriad of
examples in the literature for their uses.[74, 75] Genetically-encoded systems
are uniquely suited for imaging applications because their spatiotemporal activity
can be tailored based on the selection of proteins used as the molecular
recognition element and reporter.

However, these systems have also found

some application in in vitro sensing applications due to relative ease of design
and preparation when compared to chemically-modified biosensors.[72, 76]
There are a number of well-studied strategies used in the development of
genetically-encoded biosensing systems (Figure 1.5).

The most common

reporter molecules employed in the design of genetically-encoded systems are
GFP and its variants and aequorin, thus the examples discussed herein will focus
on these proteins. In the first strategy, an intramolecular Förster Resonance
Energy Transfer (FRET) approach is used. Briefly, FRET is a phenomenon in
which a donor molecule is excited and then nonradiatively transfers a portion of
its excited-state energy to a proximal (typically 10-100 nm) acceptor molecule
which is in turn promoted to an excited state and undergoes fluorescence. Upon
analyte binding, a conformational change occurring in the binding region results
in a change in the distance between the donor and acceptor. This change in
distance manifests as a change in FRET efficiency resulting a change in
signal.[77] The second strategy is also FRET-based, but relies instead on an
intermolecular FRET approach.

In this strategy, the donor and acceptor are

located on two different proteins. Upon the binding or association of these two
proteins, the donor and acceptor are brought closer together, leading to an
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increase in FRET. This approach is most applicable to studies of protein-protein
interactions.[78] The third strategy is referred to as bimolecular complementation
or simply as the “molecular switch” approach. In this design, a fluorescent or
bioluminescent protein is rationally designed such that the amino acid sequence
is split into two truncated fragments which, upon being placed within proximity of
one another, can reassemble to form a functional reporter protein.

Each

fragment of the reporter molecule can then be fused to either end of a sensing
protein such that upon analyte binding, the complimentary fragments are either
pulled apart or brought together, resulting in a decrease or increase in signal,
respectively.[72, 79] The fourth strategy is a variation of the third strategy in
which truncated fragments of a sensing protein are placed at either end of an
intact reporter protein. In this strategy, the binding event causes the sensing
protein to reassemble which perturbs the structure of the reporter protein, thus
resulting in a change in signal. In the fifth strategy, the reporter protein itself is
engineered such that it displays a change in signal upon response to desired
stimuli without the need for an exogenous sensing protein.[80-82] The sixth and
final strategy is an extension of the fifth in which the sensing protein produces a
measurable change in signal without the need for an exogenous reporter protein.
Typically, this is accomplished by monitoring changes in intrinsic tryptophan
fluorescence in a protein upon interaction with an analyte.[83, 84]

B. Chemically-modified Biosensing Systems
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In contrast to genetically encoded protein-based biosensing systems,
chemically-modified biosensors, as their name suggests, must be altered in
some way after isolation of the sensing protein. Typically, this is accomplished
by the covalent attachment of a small fluorescent organic molecule at a location
within the protein structure which experiences a change in conformation upon
ligand binding. As a result, the ligand-binding event causes a change in the
microenvironment around the environmentally-sensitive fluorophore, resulting in
a change in measured fluorescence intensity.

Site-specific modification of

proteins is most commonly accomplished by engineering the protein to contain a
unique cysteine residue within the protein at the desired location and subsequent
modification

by

a

fluorophore

using

well-established

sulfhydryl-reactive

chemistry. The carefully-selected fluorophore can be sensitive to changes in pH,
polarity, hydrophobicity, or other factors. As an alternative approach, a FRETbased strategy can be employed in which a sensing protein is modified with two
fluorophores, a donor/acceptor pair, such that the ligand binding event alters the
distance between the donor and acceptor resulting in a change in FRET. In this
strategy, either the donor or acceptor can also be a genetically encoded reporter
such as GFP or one of its variants.
The phenomenon of the alteration of fluorophore response in regards to its
microenvironment is termed solvatochromism. These changes in fluorescence
intensity can result from a number of factors including solvent polarity and
viscosity, rate of solvent relaxation, probe conformational changes, rigidity of the
local environment, internal charge transfer, proton transfer and excited state
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reactions, probe-probe interactions, and changes in radiative and non-radiative
decay rates.[85] When a fluorophore is bound to a location within a protein that
undergoes a dramatic conformational change, one or more of the factors above
may be altered, thus altering the spectral characteristics of the fluorescence
emission (intensity, lifetime, wavelength maxima, etc).

Because of the

complexity of these processes, it is often difficult to determine the contribution of
each of these factors to the change in the fluorescence that results from a
change in protein conformation.

Regardless, if this change in fluorescence

emission follows a concentration-dependent response to the ligand, then this
chemically-modified protein can be used for the development of a biosensing
system.
Because these organic fluorophores are typically small molecules, this
approach has the advantage of introducing a less pronounced disturbance in the
sensing protein than the genetic fusion to a large reporter protein, thus there is a
reduced chance of a detrimental effect on the activity of the sensing protein.
Additionally, the variety of commercially-available fluorophores allows for the
tailoring of spectral properties (wavelength, lifetime, quantum yield, etc) of the
biosensing system.

While some degree of customization is possible for

genetically-encoded systems, the availability of mutants of reporter proteins with
varying spectral properties is more limited.

SELECTION AND DESIGN OF MOLECULAR RECOGNITION ELEMENTS
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Integral to the design of a protein-based sensing system is a molecular
recognition element capable of accurately detecting the desired analyte with
appropriate sensitivity and selectivity.

As mentioned above, many types of

proteins can be employed in the design of a protein-based sensing system.
Among these are chemotaxis/transport proteins, antibodies, enzymes, regulatory
proteins, etc.

Each of these types of proteins has been employed in the

development of biosensing systems using different strategies to take advantage
of their unique characteristics and advantages.

A. Chemotaxis/transport Periplasmic Binding Proteins
Periplasmic binding proteins (PBPs) have been explored thoroughly as
recognition elements for use in protein-based biosensing systems.

PBPs

function as transporters for their specific ligands across the periplasmic space.
In general, members of this protein family selectively bind their respective target
ligands with binding affinities in the 0.01-10 µM range.[86] Although there is
great variety in their ligand specificity and amino acid sequence, these proteins
typically have an overall conserved structural motif.[87] In general, PBPs consist
of two globular domains each consisting of a β-sheet region surrounded by αhelices and connected by a short “hinge” region.

(Figure 1.6)

The region

between the two domains forms a binding pocket in which the ligand binds,
triggering an overall hinge-motion conformational change in the protein. PBPs
and their derivatives have been identified for a wide-array of small molecules
including sugars[72, 88-90], metal ions[90, 91],amino acids[92],
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sulfate/phosphate[90], etc. The diversity of PBPs, their inherent selectivity, their
ease of expression and purification, and the customizability of their binding
characteristics have contributed to the intense interest in recent years regarding
their use as recognition elements in biosensing systems.

B. Antibodies
Antibodies, or immunoglobulins, are specialized proteins produced by the
immune systems of animals to recognize a foreign target called an antigen.
Generally, they are depicted as having a “Y”-shaped structure, with the antigen
binding sites located at the end of each arm of the protein (Figure 1.7). In its
most basic form, the antigen/antibody interaction can be thought of as a lockand-key interaction. Antibodies are generally produced by injecting an animal
with the antigen of interest, allowing time for the animal’s immune system to
produce antibodies as part of a natural immune response, and then harvesting
the appropriate antibodies by various methods.

This well-defined procedure

allows the production of antibodies with exceptional selectivity and affinity to a
great variety of antigens ranging from small molecules to entire proteins and
microorganisms.[93, 94]
Antibodies have been widely used as a molecular recognition element in
numerous biotechnology and biosensing applications.

Perhaps the most

common and widely used application is that of enzyme-linked immunosorbent
assays (ELISA). There are many variations of ELISA, however in the most basic
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strategy, a sample with an unknown amount of analyte/antigen is immobilized on
a surface (usually a microtiter plate), and then the sample solution is removed
and the surface is washed. Next, a solution containing a non-specific protein,
typically bovine serum albumin, is added to coat the exposed surface not
covered by the sample. Then a primary antibody with an antigen binding site for
the analyte is added and allowed to bind to the analyte on the surface.

A

secondary antibody, with an enzyme attached to it, is added next, which
recognizes the primary antibody and binds to it. Finally, an appropriate substrate
for the attached enzyme is added in order to produce an observable signal which
corresponds to the concentration of analyte/antigen present in the initial sample.
Most commonly, an enzyme-substrate pair is chose which results in a
colorimetric signal. However, alternative approaches employing bioluminescent
photoprotein such as aequorin[19], fluorescent proteins such as GFP and its
variants[95] or fluorophore-labeled antibodies also exist.

C. Enzymes
Enzymes are a class of proteins which catalyze biochemical reactions by
reducing the activation energy. Within the active site of an enzyme, a substrate
binds and is converted to a product. In complex biological systems, enzymes
must have exceptional specificity towards their appropriate substrate and an
affinity to their substrate at biologically relevant concentrations.

These

characteristics make enzymes amenable for use in the development of
biosensing systems.

Indeed, perhaps the most commercially successful
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example of a protein-based biosensing system, the personal blood glucose
meter, is an enzyme-based system usually employing the enzyme glucose
oxidase.[96]

The current generation of glucose meters are electrochemical-

based sensors which employ glucose oxidase and a mediator coupled to an
electrode for electrochemical measurement.
In

addition

to

electrochemical

approaches,

fluorescence-based

approaches are also being pursued in the development of enzyme-based
biosensors.

Enzyme activity is also often associated with a significant

conformational change which can be utilized in the development of a chemicallymodified biosensor. This has been used in the development of a biosensor for
glucose based on the enzyme glucokinase by site-specific attachment of a
fluorophore.[97]Glucokinase functions by transferring phosphate from ATP to the
C6 position on glucose. During this enzymatic reaction, a large conformational
change occurs. This conformational change can be observed as a change in
fluorescence when the enzyme is modified with an appropriate fluorophore. In
addition, some enzymes require the binding of a cofactor in addition to a
substrate.

In the case of glucose oxidase, the cofactor flavin adenine

dinucleotide which is fluorescent and displays a small change in fluorescence
upon glucose binding.[98]

D. Regulatory Proteins
Regulatory proteins, as discussed in some detail above, can also be used
in the development of a protein-based biosensing system. Regulatory proteins
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are typically quite specific to their effector molecule. Regulatory proteins, in both
positively and negatively regulated systems, typically undergo significant
conformational changes upon binding their effector molecules.

Through the

strategies described previously, these conformational changes can be followed
when coupled with either a reporter protein fusion in a genetically-encoded
strategy, or a site-specifically attached fluorophore in a chemically-modified
approach.

In either case, the resulting conformational change results in a

change in fluorescence signal intensity which can be correlated to the
concentration of the effector/analyte molecule. In one such system, the protein
MerR, which binds specifically to Hg2+ has been engineered such that upon
binding, a change in fluorescence is observed.[99]

Another example of a

regulatory protein-based sensing system is the detection of cGMP by fusing the
regulatory element of various cGMP protein kinases to variants of GFP.[100]

CONCLUSIONS AND FUTURE POTENTIAL
Continued work in the fields of cell-and protein-based biosensors should
contribute to further exploitation and enhancement of the unique advantages that
they offer in the detection of a variety of analytes in different types of samples
using diverse analytical platforms.

Cell-based biosensing systems are most

promising in their applicability to the development of rugged biosensing systems
which give some degree of bioavailability information on the target analyte. The
ruggedness of cell-based systems will only increase with the further development
of spore-based biosensing systems, which is a growing field.
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Protein-based

sensing systems, due to their rapid assay times, are the best candidate for the
development of real-time monitoring devices which are especially useful in
therapeutic and biomedical devices.
The identification of additional regulatory proteins, receptors, enzymes,
etc. should expand the ranks of chemical species that can be detected.
Moreover, the identification, characterization, and alteration of new light-emitting
bioreporters should lead to advanced, multiplexed assays capable of measuring
several analytes simultaneously. Advancements in optical instrumentation and
miniaturization should, undoubtedly, yield smaller, more rugged, less expensive
methods along with the selectivity and sensitivity afforded by these genetically
engineered cells.

Miniaturization to array-based or microfluidic chip-based

platforms reduces volumes of reagents and samples as well as wastes produced.
There is no doubt that the future is bright for cell- and protein-based
bioluminescent biosensors as they will find further application in the fields of
environmental monitoring, toxicology, pharmacology, drug-screening, and
medical/clinical applications.
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STATEMENT OF RESEARCH
The underlying theme of the work presented here is to engineer bacterial
cells and proteins to improve their response characteristics such that they can be
integrated into biosensing systems.

Nature has devoted billions of years to

evolving the diversity of biological functionalities, which is evident in the variety of
organisms that today inhabit all of the environments of Earth ranging from
rainforests to water reservoirs beneath the South Pole to volcanic vents on the
ocean floor to boiling hot, acidic mineral springs.

Biological moieties (i.e.,

proteins, enzymes, tissues, and whole cells) have developed mechanisms to
detect and respond to very specific chemical species in complex mixtures as well
as tolerate and thrive in harsh living environments.

Here, we aim to take

advantage of the exceptional inherent selectivity, sensitivity, and stability that
exists throughout the natural world in the development of analytical systems to
address challenges regarding the detection of both environmentally- and
physiologically-relevant small molecules. The work presented in this dissertation
was guided by the following hypotheses:


Regulatory genetic circuits from a microorganism that respond to a
specific small molecule effector can be exploited by replacing the genes
regulated in the native organism with an appropriate reporter gene, thus
allowing detection and quantification of the effector molecule to which the
regulatory system responds to.
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By isolating and rationally engineering appropriate protein (i.e., hingemotion periplasmic chemotaxis proteins and regulatory proteins) that
serve as the biorecognition element in a biosensing system, we can attain
the required selectivity and sensitivity needed to detect small molecules of
interest in complex sample matrices.



Utilizing a protein from a hyperthermophile, Thermotoga maritima, we can
develop a protein-based sensing system with remarkable thermal stability.
This increased stability results in a sensing system that is rugged enough
to operate at physiological temperatures for extended periods of time.
Additionally, the improved stability makes this sensing system amenable
to storage and transport in extreme environments.
The work presented here describes research that sets out to explore the

hypotheses set forth above. Biosensing systems have been developed based
upon both intact living cells, as well as isolated regulatory and binding proteins.
Through each of these projects, we set out to maintain the desirable
characteristics inherent in the native biological moieties while rationally
engineering them as appropriate to tailor other characteristics (i.e., binding
affinity, thermal stability, and selectivity) when appropriate.

Below is a brief

description of the chapters to follow:


Chapter two describes the development of a whole-cell sensing system for
the detection of hydroxylated polychlorinated biphenyls (OH-PCBs). The
regulatory protein (HbpR) and promoter (PhbpCAD) from the organism
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Pseudomonas azelaica were engineered to regulate the expression of the
bioluminescent reporter protein, bacterial luciferase (LuxAB). The result is
a bacterial cell that produces bioluminescence whose intensity can be
correlated to the concentration of OH-PCBs that are present in
environmental or biological samples.


Chapter three details the development of a protein-based sensing system
based upon the aforementioned HbpR regulatory protein. This protein
undergoes a drastic conformational change upon effector molecule
binding. By labeling the native cysteines present in the protein with an
environmentally-sensitive fluorophore, we were able to observe a
concentration-dependent change in fluorescence in response to the
concentration of OH-PCBs present.



In chapter four, the development of a protein-based sensing system for
glucose based upon the periplasmic glucose bindign protein (GBP) from
E. coli is described. Protein-based sensing systems using GBP labeled
with an environmentally-sensitive fluorophore have been previously
developed with binding affinities in the micromolar range. In order to shift
the binding affinity into the physiologically-relevant millimolar range,
truncated fragments of native GBP (tGRPs) were designed and
characterized.



The design and characterization of a protein-based sensing system for
glucose based upon GBP from the hyperthermophile Thermotoga
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maritima is described in chapter five. The biosensing system presented
here differs from those presented in the previous chapters, in that the
source of fluorescence measured is the protein’s intrinsic tryptophan
fluorescence.
step.

This eliminates the need for an extra chemical labeling

Additionally,

by

employing

a

binding

protein

from

a

hyperthermophile, exceptional thermal stability has been observed,
resulting in a remarkably rugged biosensing system.

Copyright © Kendrick Bruce Turner 2011
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CHAPTER TWO
HYDROXYLATED POLYCHLORINATED BIPHENYLS DETECTION BASED
ON A GENETICALLY ENGINEERED BIOLUMINESCENT WHOLE-CELL
SENSING SYSTEM
Chapter reprinted from Turner, et al.; Analytical Chemistry, 2007, 79, 5740-5745,
by permission of American Chemical Society, copyright (2007).

INTRODUCTION
Since the 1970s, the apparent toxicities of polychlorinated biphenyls
(PCBs) have been scrutinized in much detail.

PCBs have been shown in

numerous studies to contribute to negative health effects[101-104] and to be
persistent in biological and environmental samples.[105]

Hydroxylated PCBs

(OH-PCBs) have also been more closely examined as potentially exhibiting
significant toxic health effects. OH-PCBs have been detected in the environment
at concentrations as much as 3.5 times that of PCBs, possibly originating from
sewage treatment plants and byproducts of industrial-scale reactions involving
biphenyl and biphenylol.[106]

Additionally, OH-PCBs are also present in

biological fluids as metabolites of PCBs.[105]

Many OH-PCBs have been

identified in human serum samples and may be present at concentrations
comparable to the parent PCBs.[101] It has been shown that some OH-PCBs
have estrogenic and antiestrogenic activities in various mammalian models,[101104] inhibit gap junctional intercellular communication,[103] activate aryl
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hydocarbon receptors,[103] and form DNA adducts leading to damage of
DNA.[107]
Due to the toxicity and environmental and biological persistence of OHPCBs, it is necessary to have efficient and economical methods to detect and
quantify them. Currently, the methods of choice are GC-MS and LC-MS.[108]
These methods have excellent detection limits and can effectively identify and
quantify OH-PCBs.

However, sample extraction, cleanup and derivatization

steps are required for analysis.

These factors combined with the expenses

associated with instrumentation and the need for trained laboratory technicians
quickly drives up the cost and time required for analysis.
Alternatively, whole-cell sensing systems provide several advantages over
traditional techniques. Most notably, the speed of analysis is increased due to
the lack of need for extensive sample preparation steps and the ability to
evaluate multiple samples in one analytical run. Whole-cell sensors, due to the
inherent selectivity of the recognition/regulatory proteins involved, can be used in
complex sample matrices without significant impact from interferants. In addition,
a whole-cell sensing system could be developed into a field-portable assay and
used as an on-site screening tool for both environmental and biological samples,
allowing for a more effective selection of samples to be evaluated in more detail.
Lastly, information on bioavailability of analytes is obtained with whole-cell
sensing systems, which facilitates the prediction of fate and effect of the
pollutants for toxicological studies.
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A common strategy in the development of a whole-cell sensing system is
placing a gene which encodes for a reporter protein under the control of a
specific recognition element, such as a regulatory protein, for the analyte of
interest as shown in Figure 2.1. Biosensors of this type have been developed for
a variety of analytes. More in-depth information and examples can be found in a
number of reviews.[109-111]

Specifically, we have developed a whole-cell

sensing system for the detection of OH-PCBs by employing the strain
Pseudomonas azelaica HBP1.

This bacterium contains the hbpCAD genes,

which are responsible for the degradation of hydroxylated biphenyls.

The

expression of these genes is negatively regulated by a regulatory protein
encoded by the gene hbpR located upstream from the hbpCAD genes. A strain
of Escherichia coli carrying a recombinant plasmid consisting of the luxAB
reporter gene, coding for bacterial luciferase, under control of the HbpR
regulatory protein was constructed[112] and employed as a whole-cell sensing
system in the present study. In the presence of analytes, such as OH-PCBs, the
regulatory protein HbpR activates transcription through the hbp promoter
resulting in the expression of the reporter gene. This expression can then be
monitored by measuring bioluminescence emission after addition of decanal, a
substrate for luciferase. Within a certain range of analyte concentrations, the
expression of the reporter gene is dose-dependent, therefore, the intensity of the
analytical signal is directly related to the amount of target compound.
Analyzing the concentration of OH-PCBs in serum samples as a
biomarker of PCB exposure is essential for toxicological studies and remediation
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purposes. The hydrophilic nature of the hydroxyl group in OH-PCBs suggests
that these chemicals may be readily excreted from the body. However, the most
predominant PCB metabolites found in biological fluids contain between five to
seven chlorines with one hydroxyl group in the biphenyl ring.[113, 114]
Therefore, the possibility of retention rather than excretion also exists due to the
increased hydrophobicity contributed by physicochemical properties of chlorines
attached to the biphenyl backbone. Moreover, their high lipophilicity and affinity
to certain proteins such as the thyroxin-transporting protein, transthyretin (TTR)
lead to the retention of OH-PCBs in different body compartments, mainly in
blood.[115]
In this study, we have employed a genetically engineered bacterium to
develop a whole-cell sensing system to detect the presence of a variety of OHPCBs in both environmental and biological samples. This sensing system has
been optimized with respect to important assay conditions, and the feasibility of
the application of this system as a screening tool has been discussed.

MATERIALS AND METHODS
Chemicals and media
2-Hydroxybiphenyl was obtained from Sigma-Aldrich Corp. (St. Louis,
MO). In Table 2.1, OH-PCBs No 2, 5, 6, and 8-12 were obtained from
Accustandard Inc. (New Haven, CT), OH-PCBs No 3 and 4 were obtained from
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Table 2.1. Response of the whole-cell sensing system to various OH-PCBs.
No

Compound

log (A/Ao)a

- log ED50b

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

2-Hydroxy-4’-chlorobiphenyl
2-Hydroxy-3’4’-dichlorobiphenyl
2-Hydroxy-3,5-dichlorobiphenyl
2-Hydroxy-2’,3,5’-trichlorobiphenyl
2-Hydroxy-2’,4’,6’-trichlorobiphenyl
2-Hydroxy-2’,5,5’-trichlorobiphenyl
2-Hydroxy-3’,4’,5-trichlorobiphenyl
2-Hydroxy-3’,5,5’-trichlorobiphenyl
2-Hydroxy-2’,3’,4’,5’-tetrachlorobiphenyl
2-Hydroxy-2’,3’,5’,6’-tetrachlorobiphenyl
2-Hydroxy-2’,4’,5,6’-tetrachlorobiphenyl
2-Hydroxy-2’,3’,4’,5,5’-pentachlorobiphenyl
3-Hydroxy-4’-chlorobiphenyl
4-Hydroxy-4’-chlorobiphenyl
4-Hydroxy-2’,3-dichlorobiphenyl
4-Hydroxy-2’,5’-dichlorobiphenyl
4-Hydroxy-3,3’-dichlorobiphenyl
4-Hydroxy-3,4’-dichlorobiphenyl
4-Hydroxy-3’,4’-dichlorobiphenyl
4-Hydroxy-3,5-dichlorobiphenyl
4-Hydroxy-2’,3,5-trichlorobiphenyl
4-Hydroxy-3,3’,4’-trichlorobiphenyl
4-Hydroxy-3,3’,5-trichlorobiphenyl
4-Hydroxy-3,3’,5’-trichlorobiphenyl
4-Hydroxy-3,4’,5-trichlorobiphenyl
4-Hydroxy-3,3’,4’,5-tetrachlorobiphenyl
4-Hydroxy-2’,3,4’,5-tetrachlorobiphenyl

0.44
0.88
0.50
0.56
0.37
0.49
0.24
0.22
0.47
0.48
0.20
0.35
0.46
0.31
0.75
0.61
0.64
0.60
0.41
0.63
0.32
0.82
0.42
0.50
0.38
0.21
0.12

1.76 ± 0.37
5.66 ± 0.07
2.09 ± 0.24
3.86 ± 0.25
3.21 ± 0.06
4.17 ±0.03
4.84 ± 0.15
5.16 ± 0.32
3.21 ±0.06
4.47 ± 0.11
3.36 ± 0.62
4.35 ± 0.76
2.29 ±0.24
2.87 ± 0.19
4.43 ±0.09
3.46 ± 0.07
4.58 ± 0.14
3.75 ± 0.05
3.49 ± 0.69
3.49 ± 0.05
3.75 ± 0.05
4.79 ± 0.05
2.49 ± 0.11
4.21 ±0.06
3.40 ± 0.14
3.49 ± 0.30
4.42 ± 0.26

a

Detection
Limit (M)c
1.0×10-6
5.0×10-7
5.0×10-5
1.0×10-5
1.0×10-8
5.0×10-6
1.0×10-9
1.0×10-7
5.0×10-5
5.0×10-6
1.0×10-6
1.0×10-6
1.0×10-7
5.0×10-5
1.0×10-8
1.0×10-7
1.0×10-8
1.0×10-6
1.0×10-8
5.0×10-7
1.0×10-6
1.0×10-7
1.0×10-6
1.0×10-6
1.0×10-6
1.0×10-5
1.0×10-7

The response ratio (A/Ao) was calculated by dividing the maximum bioluminescence signals for

each hydroxylated PCB (A) by the bioluminescence signals for the blank (Ao)
b

ED50 was defined as concentration at 50% maximum induction, and was calculated by using

GraphPad Prism 4.0 software.
c

Detection limit was defined as the analyte concentration that corresponds to a signal-to-noise
ratio of 3.
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Ultra Scientific Inc. (North Kingstown, RI), and OH-PCBs No 1, 7, and 13-27
were kind gifts from Hans Lehmler at the University of Iowa. The purities (≥
95.0%) of these synthesized OH-PCBs were verified by Agilent GC-MS 5975
prior to experiments.
Dimethyl sulfoxide (DMSO, ≥ 99.9%, for molecular biology), n-decanal (≥
99%, for GC, liquid), ethanol (anhydrous, ≥ 99.5%, 200 proof), glycerin (meets
USP testing specifications), and human serum (from clotted human male whole
blood, sterile-filtered, mycoplasma tested, virus tested) were obtained from
Sigma-Aldrich Corp. (St. Louis, MO). Deionized distilled water was produced by
a Milli-Q water purification system (Millipore, Bedford, MA).
Escherichia coli strains were grown at 37 oC on Luria-Bertani (LB) medium
(BIO 101, Vista, CA) containing ampicillin (100 µg/mL, Sigma-Aldrich Corp., St.
Louis, MO). For the luciferase induction assay, mineral medium (MM) defined by
Gerhardt et al.,[116] was prepared and supplemented with 0.01% tryptone,
0.005% yeast extract, and 10 mM D-(+)-glucose before use, as described by
Jaspers et al. [112] MM (per liter) was prepared from the ingredients: 1.00 g of
NH4Cl, 3.49 g of Na2HPO4·2H2O, 2.77 g of KH2PO4, 20 mL of Hunter’s vitaminfree mineral base, and 2.0 mL of a vitamin solution, adjusted to pH 6.8. Hunter’s
vitamin-free mineral base contained (per liter): 10 g of nitrilotriacetic acid
(neutralize with 6.00 g of KOH), 14.5 g of MgSO4·7H2O, 3.33 g of CaCl2·2H2O,
9.74 mg of (NH4)6Mo7O24·4H2O, 99 mg of FeSO4·7H2O, and 50 mL of the Metals
44 solution. The composition of Metals 44 (per 100 mL) was as follows: 387 mg
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of Na4EDTA·4H2O, 1.10 g of ZnSO4·7H2O, 914 mg of FeSO4·7H2O, 154 mg of
MnSO4·H2O, 39.2 mg of CuSO4·5H2O, 24.8 mg of Co(NO3)2·6H2O, 17.7 mg of
Na2B4O7·19H2O, and was neutralized with H2SO4. The vitamin solution (per 100
mL) was prepared by mixing 0.50 mg of biotin, 50 mg of nicotinic acid, and 25 mg
of thiamine hydrochloride. MM was sterilized and stored at 4 oC before use. All
chemicals for MM preparation were purchased from Sigma-Aldrich Corp. (St.
Louis, MO), and were at least cell culture tested grade.

Preparation of E. coli cells harboring plasmid pHYBP109
Cells were obtained as a frozen glycerol stock. A stab was taken from this
stock and grown overnight at 37 °C in a culture tube containing 2 mL of LB
medium and ampicillin (100 µg/mL). The following day, the 2 mL culture was
transferred to a 1 L flask containing 250 mL of LB medium and grown at 37 °C to
an optical density at 600 nm (OD600) of approximately 0.90. The cells were then
dispensed into 1.5 mL microcentrifuge tubes in 1 mL aliquots and stored at -80
°C until use. A volume of 50 µl of sterilized glycerin was added to each 1 mL
stock of cells for preservation purposes. Unless otherwise specified, all the cells
were grown in a rotary shaker at 200 rpm.

Detection of compounds in dimethyl sulfoxide
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Stock solutions of each compound were prepared at a concentration of 1 x
10-2 M by dissolving the appropriate mass of each compound in 1.0 mL of DMSO
in a microcentrifuge tube and vortexing until dissolved. From these, solutions in
a concentration range of 5.0×10-3 - 1.0×10-9 M were prepared by serial dilution of
the original stock solution in DMSO. In addition, a blank was prepared containing
only DMSO. Each set of solutions was prepared fresh and the 1 x 10-2 M stock
solutions were saved and frozen at -20 °C after use.
Immediately prior to use in each assay, a microcentrifuge tube containing
a 1 mL aliquot of cells was removed from the -80 °C freezer and placed in a room
temperature water bath for 2 minutes, and then on ice.

For the final assay

solution, 1.9 mL of MM, 33 µL of thawed cell suspension, and 20 µL of a
compound at each concentration along with a blank as prepared above were
dispensed into a series of 14 mL culture tubes in triplicate. These tubes were
placed at 30 °C on an orbital shaker at 225rpm for a 4 hour incubation period.
Following incubation, a volume of 200 µL of the cell suspension from each
culture tube was dispensed into the wells of a 96-well microtiter plate in triplicate.
A volume of 100 µL of stock n-decanal substrate solution (2 mM in 1:1
ethanol/H2O) was added into the reaction assay by automated injection for the
bioluminescence signal measurement. Light output was integrated from 5 s to 15
s after n-decanal injection for each of the wells in the plate using a POLARstar
OPTIMA luminometer (BMG Labtech, Offenburg, Germany).
signal was expressed as relative light units (RLU).
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The total light

For experimental optimization, the general protocol described above was
employed, unless otherwise specified in the text. All assays were conducted in
triplicate.

Detection of model compound in human serum
2-Hydroxy-3’,4’-dichlorobiphenyl was used to evaluate the assay in human
serum. This compound was prepared as above in a concentration range from 1
x 10-2 M – 1 x 10-8 M in DMSO along with a blank containing only DMSO. In a
separate set of microcentrifuge tubes, 10 µL of each of these solutions was
dispensed into 90 µL of human serum. This resulted in serum samples with the
compound of interest present in a range of 1 x 10-3 M – 1 x 10-9 M along with a
blank. Additionally, a set of samples was prepared using deionized water instead
of human serum as a comparison. These solutions were then used to complete
the assay as described above.

Detection of a compound mixture in human serum
A mixture of the following 10 OH-PCBs was prepared at a concentration of
1 x 10-3 M with respect to each individual compound in DMSO: 2-hydroxy-3’,4’dichlorobiphenyl,

4-hydroxy-3,3’,4’-trichlorobiphenyl,

2-hydroxy-3’,4’,5-

trichlorobiphenyl, 2-hydroxy-3’,5,5’-trichlorobiphenyl, 3-hydroxy-4’-chlorobiphenyl,
4-hydroxy-2’,3,4’,5-tetrachlorobiphenyl,

4-hydroxy-2’,5’-dichlorobiphenyl,
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4-

hydroxy-3’,4’-dichlorobiphenyl, 4-hydroxy-3,3’-dichlorobiphenyl, 4-hydroxy-2’,3dichlorobiphenyl.

To prepare this solution, 10 µL of the 1.0 × 10-2 M stock

solution of each compound was dispensed into a single microcentrifuge tube.
Serial dilutions were made using this solution to create a mixture in DMSO in a
concentration range of 1 x 10-3 – 1 x 10-8 M with respect to each compound and a
concentration of 1 x 10-2 M – 1 x 10-7 M with respect to total OH-PCBs. In a
separate set of microcentrifuge tubes, 10 µL of each of these solutions was
dispensed into 90 µL of human serum, yielding samples of the mixture in human
serum in a concentration range of 1 x 10-4 – 1 x 10-9 M with respect to each
compound. These samples were then used to complete the assay as described
above.

Statistical analysis
The results presented are the averages of the values obtained in three
independent experiments. GraphPad Prism 4.0 (GraphPad Software Inc., San
Diego, CA) was used to generate non-linear best-fit lines of the data.

RESULTS AND DISCUSSION
The strain Pseudomonas azelaica HBP1 is able to use hydroxylated
biphenyls as sole carbon and energy sources.

The mechanism for the

degradation of 2-hydroxybiphenyl by P. azelaica HBP1 has been well
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characterized.[117] The metabolism involves three enzymes encoded by the
hbpCAD genes, which are negatively regulated by the HbpR protein. To study
the PhbpC promoter activity of P. azelaica HBP1, a plasmid (designated as
pHYBP109)

containing

hbpR-PhbpC-luxAB

fusion

was

constructed

and

transformed to E. coli by Jaspers et al.[112] Induction experiments were carried
out using 2-hydroxybiphenyl. Increasing bioluminescence signals upon induction
with 0.2 mM of 2-hydroxybiphenyl for increasing induction times suggested the
direct activation of PhbpC promoter by the compound binding to the HbpR
protein.[112] In our laboratory, initial experiments were conducted by treating
these recombinant E. coli cells with varying concentrations of 2-hydroxybiphenyl.
A preliminary detection limit of 1 x 10-6 M could be obtained (data not shown),
under the experimental conditions reported by Jaspers et al.[112] The detection
limit is defined as the minimum analyte concentration that corresponds to a
signal-to-noise ratio of 3.
A whole-cell sensing system is a genetically modified system constructed
in such a way that in the presence of an analyte, expression of a reporter protein
is triggered. In the plasmid used in this study, hbpR, the gene encoding for the
HbpR protein, is positioned upstream from the luxAB genes, which code for the
bioluminescent reporter protein, luciferase.

In this way, the expression of

luciferase is placed under the control of the PhbpC promoter, which is regulated by
the HbpR protein.

Thus, the expression of luciferase in E. coli harboring

pHYBP109 is mediated by the HbpR regulatory protein from the same regulatory
circuit. In the absence of hydroxylated biphenyls, the HbpR protein binds to the
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promoter and prevents the expression of luxAB genes.

In the presence of

hydroxylated biphenyls, the HbpR protein undergoes a conformational change
upon binding of the inducer molecules, causing release of the protein-inducer
complex from the promoter.

As a result, expression of the reporter protein

occurs.
In a study carried out by Jaspers et al. to evaluate the selectivity of the
HbpR protein, a group of chemicals such as biphenylic compounds, polycyclic
aromatic hydrocarbons, and monoaromatic hydrocarbons, among others, were
screened using engineered bacteria.[112] It was found that only a few structurally
similar chemicals containing the biphenyl backbone showed significant activity.
In fact, when the signals were normalized to the response to 2-hydroxybiphenyl
at a concentration of 2 mM, relative luciferase activities more than 32% were
observed for only a narrow range of compounds. Additionally, some chemicals
showing activity had a hydroxyl group at the ortho biphenyl ring position. On the
other hand, biphenyl, chlorobiphenyl, or compounds with a monoaromatic
structure failed to show activity. Because of the selectivity of the HbpR protein in
recognizing compounds with biphenyl backbone and a hydroxyl group, we
envisioned that employing engineered E. coli harboring plasmid pHYBP109 as a
whole-cell sensing system would permit us to detect a group of structurally
similar OH-PCBs.

Moreover, the broad inducer range of TbuT[118] and

XylR[119], which belong to the same NtRC family of proteins as HbpR, further
supported the investigation of the inducer spectrum of HbpR protein by exposing
the recombinant cells to OH-PCBs. As a pioneer study, cells were exposed to
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five randomly selected OH-PCBs. Significant increase of the bioluminescence
signal as compared to a blank was observed for all five compounds tested. The
maximum signal ratio of 1.72 ± 0.11 (mean ± standard deviation; n=3) was found
by using 2-hydroxy-3’,4’-dichlorobiphenyl at a concentration of 1 x 10-3 M after 2h
incubation period.

Thus, this chemical was used as a model compound for

further optimization of assay parameters.
Because only the regulator and promoter region of the hbp operon was
inserted into the luciferase expression vector, the degradation of OH-PCBs by
the cells is unlikely. For this reason, the toxicity of OH-PCBs to the bacteria used
in our assay was evaluated. Cell growth was monitored with/without the addition
of 2-hydroxy-3’,4’-dichlorobiphenyl, at a final concentration of 1 x 10-5 M, to the
medium containing cells harboring the pHYBP109 plasmid. Optical densities at
600 nm (OD600) were checked every hour for 8 hours. Observed differences in
OD600 of less than 10% between the two cell growth curves indicate that the
toxicity of the compound is negligible at the tested concentration.
Important assay parameters were optimized in order to improve the overall
performance of the biosensing system. Among these were the growth stage at
which the cells were harvested, the storage method of the harvested cells, and
the length and temperature of the incubation of the cells with the analytes. The
optimum biosensing conditions were found to be harvesting cells at an optical
density of approximately 0.9 measured at 600 nm, storage of the cells at -80 ºC
until use, and incubating the cells at 30 ºC for 4 h during the assay.
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Once all biosensing system parameters were optimized, the genetically
engineered whole cells were exposed to varying concentrations of 2-hydroxy3’,4’-dichlorobiphenyl. An increase in the bioluminescence signal was observed
with increasing concentration of the compound as shown in Figure 2.2. Data
points were fitted with a sigmoidal dose-response curve, and a correlation
coefficient R2 of 0.9977 was obtained. The detection limit falls in the order of 10-8
M. When the analyte concentration was in the range of 1 x 10-7 M to 1 x 10-3 M,
a rapid increase of the bioluminescence signal was observed. Concentrations of
the model compound higher than 1 x 10-3 M caused the bioluminescence signal
to decrease significantly (data not shown). This observation is in agreement with
the data published by Hay et al. for the detection of 2,4-dichlorophenol using a
bioluminescent whole-cell reporter.[120]

It is speculated that at higher

concentrations of the analyte, there is a toxic effect, which leads to a reduced
number of living cells and a subsequent significant decrease in the response.
The next step in our research aimed at evaluating the response of the
whole-cell sensor to a variety of OH-PCBs. However, it is difficult to assess the
most predominant OH-PCBs in human serum[104] because of the unavailability
of these compounds for use as standards from commercial sources. For that, a
range of 27 commercially available OH-PCBs at various concentrations were
tested. A dose-dependent response was observed for all of these compounds.
A representative example for 4-hydroxy-3,3’,4’-trichlorobiphenyl is reported in
Figure 2.2. The data from each analyte was fit with a sigmoidal dose-response
curve, and parameters such as log ED50 and log (A/Ao) were calculated and
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Figure 2.2. Dose-response curves of the whole-cell sensing system. The
curves were obtained with 2-hydroxy-3’,4’-dichlorobiphenyl (■) and 4-hydroxy3,3’,4’-trichlorobiphenyl (▼) under optimized experimental conditions.

The

bioluminescence signals have been corrected with respect to the blank. Values
represent the means ± standard deviation of triplicate determinations.
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summarized in Table 1.

ED50 was defined as the concentration at 50% of

maximum induction, and was calculated by using GraphPad Prism 4.0 software.
The

induction

ratio

(A/Ao)

was

calculated

by

dividing

the

maximum

bioluminescence signal for each hydroxylated PCB (A) by the bioluminescence
signal for the blank (Ao). The maximum induction levels and the concentrations
to achieve the maximum induction varied among the analytes tested.

The

dynamic range for the detection of hydroxylated PCBs covered two to five orders
of magnitude. The detection limits ranged from 1 x 10-9 to 1 x 10-5 M. These
results are in agreement with previous studies which demonstrate differential
light responses in whole-cell sensing systems to various members of a class of
related compounds.[121, 122]

An attempt to explain the differences in the

responses to the chemicals, based on their molecular structure, is ongoing at this
stage.
In order to validate the response of this luciferase-based whole-cell
sensing system to the PCB metabolites in a biological matrix, human serum was
spiked with a range of concentrations of the model compound. The assay was
carried out under the optimized experimental conditions. As shown in Figure 2.3,
a dose-response curve was obtained with a log ED50 of -5.29, and a detection
limit of 5.0 × 10-8 M. Increased bioluminescence signals were observed for the
serum samples spiked with 2-hydroxy-3’,4’-dichlorobiphenyl, as compared to the
signals produced by the same analyte concentrations in the absence of the
biological matrix. It is believed that this increased signal is due to the presence
of proteins found in serum. These proteins may prevent the analyte from
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Figure 2.3.

Dose-response curves of the whole-cell sensing system in

serum. The curves were obtained with 2-hydroxy-3’,4’-dichlorobiphenyl in 90%
water/10% DMSO (■) or 90% serum/10% DMSO (▼). The bioluminescence
signals have been corrected with respect to the blank. Values represent the
means ± standard deviation of triplicate determinations.
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interacting with the walls of the plastic tube, thus making the analyte more
available for diffusion into the cells.

Overall, the resultant bioluminescence

response of the whole-cell sensing system to the model compound in serum
demonstrates the feasibility of direct detection of OH-PCBs in serum samples.
In real samples, PCB metabolites are present as mixtures. Various
contamination patterns of hydroxylated PCBs have been reported in the literature
for fish plasma [123], polar bear whole blood,[124] and human whole blood,[125]
plasma,[126-129] serum[114, 130] and cerebrospinal fluid samples[108].
Additionally, the ratios of total OH-PCBs to total PCBs calculated were around 456 % in human plasma[126] or even found to be 4-8 times higher in the whole
blood of polar bears[124]. In our laboratory, the responses of the whole-cell
sensing system to a model mixture of 10 OH-PCBs were tested. The obtained
dose-response curve with a detection limit of 5.0 × 10-8 M suggests the potential
for employing this sensing system as a screening method for multiple OH-PCBs
contaminated samples.

Notably, the application of this whole-cell sensing

system to the detection of OH-PCBs in biological and environmental samples
could remarkably reduce the analysis time and cost posed by currently used
conventional methods, such as GC or LC methods. Further studies utilizing this
whole-cell sensing system will enable us to monitor the bioavailable PCB
metabolites in large pools of environmental and biological samples. This will
provide a new insight into the pollution status at certain sites for better
understanding of the current ecological conditions of the living environment.

66

CONCLUSIONS
In this work, a rapid and sensitive sensing system for the detection of
hydroxylated PCBs based on genetically engineered whole cells has been
developed. Additionally, the performance of this whole-cell sensing system has
been demonstrated in a biological sample matrix. The results achieved suggest
that the sensing system may find applications in biomedical analysis as well as in
the environmental monitoring of hydroxylated PCBs.

The ruggedness of the

proposed sensing system can be further improved by employing lyophilized cells,
which can be easily stored and transported to the field, and reconstituted for later
use. Upon miniaturization and integration into an appropriate assay platform, we
envision this system being developed into a rapid, high-throughput, field-portable
method for the detection of hydroxylated PCBs in both environmental and
biological samples.
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CHAPTER THREE
ENGINEERING THE TRANSCRIPTIONAL REGULATORY PROTEIN, HbpR,
TO DEVELOP A SCREENING METHOD FOR HYDROXYLATED
POLYCHLORINATED BIPHENYLS

INTRODUCTION
Polychlorinated biphenyls (PCBs) are a class of 209 congeners of
persistent, toxic organochlorine compounds that have been exhaustively shown
to contribute to a variety of negative health outcomes in humans. Specifically,
PCBs have been shown to affect neurological and cognitive development,[131,
132] increase the risk of childhood leukemia,[133] reduce the success of in vitro
fertilization attempts,[134] and cause endocrine system disruption.[135, 136]
These compounds are nearly ubiquitous in the environment, as well as present in
some homes and buildings due to their many years of use in applications such as
plasticizers, surface coatings, inks, adhesives, flame retardants, duplicating
paper, wire insulators, caulking materials, elastic sealants, heat insulation, and
electrical transformers.[137]

PCBs are classified as persistent organic

compounds, meaning that once present in the environment they are not easily
degraded by natural physical, chemical or biological processes. Additionally,
PCBs are not readily eliminated from most complex organisms and exhibit a high
degree of lipophilicity. As a result, there is a bioaccumulation effect for PCBs
and an increase in exposure throughout the food chain (biomagnification) and
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susceptibility of humans to exposure both from the environment and from dietary
sources.
Upon human exposure to PCBs, hydroxylated metabolites are formed in
vivo by cytochrome p450 enzymes.[138] The resulting hydroxylated PCBs (OHPCBs) are less lipophilic, thus resulting in a decreased half-life in the body from
an estimated median value of 37 years[139] to a half-life on the order of
days.[140]

Studies have shown that OH-PCBs may possess unique toxicity,

acting as endocrine disruptors,[141] increasing the formation of reactive oxygen
species,[142] and disrupting the membrane potential of neocortical cells.[143]
While OH-PCBs as a class have a relatively short biological half-life, some
congeners, particularly those derived from highly chlorinated parent PCBs, are
not easily eliminated from the body.[144] The shortened half-life and increased
hydrophilicity of OH-PCBs contribute to a lower total concentration in body fluids
and tissues when compared to their parent PCBs. Typically, the total OH-PCB
concentration is approximately an order of magnitude lower than the total PCB
concentration when measured in serum.[140] Since the serum concentration of
OH-PCBs corresponds to that of PCBs, OH-PCBs can serve as a biomarker for
PCB exposure.
Previously, we have developed a whole-cell biosensing system for OHPCBs employing the regulatory protein HbpR from Pseudomonas azelaica.[4]
HbpR is a member of the XylR/DmpR subfamily of σ54-dependent regulatory
proteins (figure 3.1).[145]

Acting as a negative genetic regulator, HbpR

undergoes a conformational change, releases from the operator region, and
69

F
Figure
3.1. Model of the
t conforrmational change
c
forr the protein, NtrC1. The
protein Hbp
pR belong
gs to a family
f
of proteins known
k
as σ54-depen
ndent
trranscription
nal regulato
ors.

The only
o
membe
er of this prrotein familyy with available

sttructural infformation iss NtrC1, sh
hown above
e. These proteins
p
con
nsist of multiple
domains:

the
t
effector-binding A-domain,
A
t
the
Q-linke
er B-domain, the ATP
Pase

binding D-d
domain. Upon
U
effecttor binding, the
active C-domain, and the DNA-b
proteins und
dergo a drastic confo
ormational change originating in the A-dom
main,
w
which
resultts in the acttivation of C-domain
C
A
ATPase
acttivity, and re
elease from
m the
operator seq
quence by the
t D-doma
ain.

70

allows transcription of genes under the control of the corresponding promoter
upon effector binding. We hypothesize that we can exploit this conformational
change in the development of a protein-based biosensing system for the
detection of OH-PCBs.

By covalently attaching an environmentally-sensitive

fluorescent molecule to cysteines in HbpR, the fluorescent signal may change in
a dose-dependent manner upon OH-PCB binding.
Protein-based sensing systems have the distinct advantage of typically
producing a sample-to-answer response much faster than cell-based sensing
systems. Previous work with HbpR suggests that the protein binds to most OHPCBs, albeit with different affinities.[4] As a result of this class-specificity and the
relatively fast assay times associated with protein-based sensing systems, we
believe that a biosensing system based on HbpR is well-suited for the
development of a screening method for large numbers of samples to select
positive samples for more labor-intensive and time-consuming analysis by
traditional methods, such as, gas chromatography/mass spectrometry. In this
work, we describe the protein engineering and fluorescent labeling of HbpR, and
the investigation of its response to OH-PCBs in buffer as well as in spiked human
serum.

EXPERIMENTAL
Reagents.

Custom oligonucleotide primers were purchased from Operon

Biotechnologies (Huntsville, AL). BamHI, EcoRI, HindIII, T4 DNA ligase, and Pfu
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DNA polymerase were purchased from Promega (Madison, WI). Luria-Bertani
(LB) broth and agar, 2-amino-2-hydroxymethyl-propane-1,3-diol hydrochloride
(Tris-HCl),

sodium

chloride,

tris(2-carboxyethyl)phosphine

and

ethylenediaminetetraacetic acid (EDTA) were purchased from Fisher Scientific
(Fair Lawn, NJ). OH-PCB reference standards for the compounds listed in table
3.1 were purchased from AccuStandard (New Haven, CT). Ampicillin sodium
salt, tetracycline, and human serum were purchased from Sigma (St. Louis, MO).
Urea, 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), and
glycerol were purchased from BDH/VWR (Bridgeport, NJ).

Dimethylsulfoxide

(DMSO) was purchased from J.T. Baker (Phillipsburg, NJ).

Isopropyl β-D-1-

thiogalactopyranoside (IPTG) was purchased from Gold Biotechnology (St.
Louis, MO). Maltose was purchased from Acros (Pittsburg, PA). QIAquick gel
purification kit and QIAprep DNA isolation kit were purchased from Qiagen
(Valencia, CA).

5-((((2-iodoacetyl)amino)ethyl)amino)naphthalene-1-sulfonic

acid (IAEDANS), TOP10F’ cells, and the vector pRSETA were obtained from
Invitrogen (Carlsbad, CA).

Ten thousand molecular weight cut-off dialysis

cassettes were purchased from Pierce (Rockford, IL). Amylose resin and the
vector pMal-p4E were purchased from New England Biolabs (Ipswich, MA).
Apparatus. PCR reactions were carried out using an Eppendorf Mastercycler
personal

thermocycler

measurements

were

(Hamburg,
performed

Germany).

using

a

Milton

Optical
Roy

density
Spectronic

(OD)
21D

spectrophotometer (Ivyland, PA). Cell lysis was performed using a Fisher Sonic
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Table 3.1. Assay response of selected OH-PCBs
Compound
2,3-Dihydroxy-3',4'-dichlorobiphenyl
2-Hydroxy-2',3',4',5,5'-pentachlorobiphenyl
2-Hydroxy-2',3,4',5',6-pentachlorobiphenyl
2-Hydroxy-2',3',4',5-tetrachlorobiphenyl
2-Hydroxy-2',3',5',6'-tetrachlorobiphenyl
2-Hydroxy-2',4',5,6'-tetrachlorobiphenyl
2-Hydroxy-2',4',6-trichlorobiphenyl
2-Hydroxy-3',4'-dichlorobiphenyl
2-Hydroxy-3',5,5'-trichlorobiphenyl
4-Hydroxy-2',3,4',5-tetrachlorobiphenyl
4-Hydroxy-2',3',5-trichlorobiphenyl
4-Hydroxy-2',4',6'-trichlorobiphenyl
4-Hydroxy-3,3',4',5-tetrachlorobiphenyl
4-Hydroxy-3,3',5'-trichlorobiphenyl
4-Hydroxy-3,5-dichlorobiphenyl

Detection
Limit (M)
N/A
1.0 x 10-6
1.0 x 10-6
1.0 x 10-7
1.0 x10-8
1.0 x 10-7
3.2 x 10-7
1.0 x 10-7
N/A
1.0 x 10-6
1.0 x 10-7
1.0 x 10-7
1.0 x 10-7
1.0 x 10-8
1.0 x 10-8
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Apparent
KD (M)
N/A
2.5 x 10-6
2.4 x 10-6
2.1 x 10-6
2.4 x 10-7
1.3 x 10-7
1.0 x 10-6
2.3 x 10-7
N/A
2.5 x 10-6
1.0 x 10-6
9.6 x 10-7
1.0 x 10-6
6.1 x 10-7
5.6 x 10-8

Dynamic Range (M)
N/A
-6
1.0 x 10 – 1.0 x 10-4
1.0 x 10-6 – 1.0 x 10-5
1.0 x 10-6 – 1.0 x 10-5
1.0 x 10-8 – 1.0 x 10-6
1.0 x 10-7 – 1.0 x 10-6
3.2 x 10-7 – 1.0 x 10-5
1.0 x 10-7 – 1.0 x 10-5
N/A
1.0 x 10-6 – 1.0 x 10-4
1.0 x 10-7 - 1.0 x 10-5
1.0 x 10-7 - 1.0 x 10-5
1.0 x 10-7 - 1.0 x 10-5
1.0 x 10-8 - 1.0 x 10-5
1.0 x 10-8 - 1.0 x 10-6

Dismembrator 500 from Fisher (Fair Lawn, NJ).

Centrifugation steps were

carried out using a Beckman Coulter Avanti J-E centrifuge from Beckman Coulter
(Palo Alto, CA).

Fluorescence measurements were performed using a BMG

Labtech POLARstar Optima microtiter plate fluorimeter from BMG (Offenburg,
Germany).
Construction of pHbpR-A-MBP plasmid. For all cloning and culturing steps,
cells were grown in LB supplemented for selection as described below. Cell
cultures were grown at 37 °C, with shaking at 250 rpm. Initially, the gene for the
A-domain of HbpR (hbpR-A) was amplified by PCR using the procedure provided
by the supplier of the Pfu polymerase. The primers used were HbpR-A-BamHI
(5’-GGTGGTGGATCCATGAAATCAAATAAAAATAATAGC-3’)

and

HbpR-A-

EcoRI (5’-GGTGGTGGATTCCGCCCACATTTCGGCGGGCTTCGC-3’).

The

template DNA used was pHYBP109 and was obtained from our previous work.[4]
PCR reaction conditions were carried out as described by the supplier’s protocol.
Briefly, the reaction mixture contained final concentrations of 2.5 µM for each
primer and 25 ng/µL of template DNA.

The temperature program used for

amplification consisted of an initial denaturation step of 95 °C for 2 min, followed
by 30 cycles of 95 °C for 1 min, 65 °C for 2 min, and 72 °C for 2 min and a final
elongation step of 72 °C for 5 min.
The resulting PCR product was purified by agarose gel electrophoresis,
and the corresponding DNA band (617 bp) was excised from the gel and purified
using the QIAquick Gel Extraction Kit. The purified PCR product, in tandem with
the vector pRSETA, was then digested with the restriction enzymes BamHI and
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EcoRI following the supplier’s protocol. The digested fragments were purified by
agarose gel electrophoresis, co-purified using the QIAquick Gel Extraction Kit,
and ligated using T4 ligase following the supplier’s protocol.

The resulting

ligation product was transformed into TOP10F’ cells, which were grown on LB
agar with ampicillin (100 µg/mL) and tetracycline (15 µg/mL) for selection.
Transformation colonies were grown overnight in LB media with ampicillin
and tetracycline. Plasmid from these cultures was isolated using the QIAprep kit,
digested with BamHI and EcoRI, and analyzed by agarose gel electrophoresis for
the correct plasmid, pRSETA-hbpR-A. The purified plasmid possessing bands of
the correct size was sequenced for confirmation. For transformants containing
plasmids with the correct sequence, glycerol stocks were prepared and stored at
-80 °C.
To prepare a plasmid for expression of the A-domain of HbpR (HbpR-A)
as a fusion to maltose binding protein (MBP), the plasmids pRSETA-hbpR-A and
pMal-p4E were digested with BamHI and HindIII. The resulting products were
purified by agarose gel electrophoresis, co-isolated from the gel using the
QIAquick Gel Extraction Kit and ligated using T4 ligase as above. The resulting
product was transformed into TOP10F’ cells and grown on LB agar with
ampicillin and tetracycline for selection.

As above, the transformants were

analyzed for the correct plasmid, pMal-p4E-hbpR-A, and candidates were sent
for confirmation by DNA sequencing.

Transformants containing the correct

plasmid were preserved as glycerol stocks at -80 °C.
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Expression and Purification of HbpR-A-MBP.

For expression of HbpR-A-

MBP, a 2.0 mL culture of TOP10F’ cells containing pMal-p4E-hbpR-A was grown
overnight in LB media supplemented with ampicillin (100 µg/mL) and tetracycline
(15 µg/mL). Two 500 mL expression cultures in LB media were inoculated the
following day using the overnight cultures and grown to an OD600 of 0.4-0.5, and
protein expression was induced by the addition of 1 mM IPTG. Expression was
carried out overnight at 37 °C.

Following expression, the cultures were

centrifuged to a pellet (10,000 x g, 20 min, 4 °C), and the supernatant was
discarded. The isolated cell pellet was used to prepare purified HbpR-A-MBP
fusion protein.
The cell pellet was resuspended in lysis buffer (20 mM Tris-HCl, 200 mM
NaCl, 1 mM EDTA, pH 7.4) and placed on ice. Cells were lysed on ice by pulsed
sonication (10 s on, 10 s off, 10 min total), and the resulting suspension was
immediately centrifuged (10,000 x g, 20 min, 4 °C) to separate the proteincontaining supernatant from the cellular debris. The supernatant was added to a
gravity-flow column containing 2 mL of amylose resin equilibrated according to
the supplier’s instructions, and the flow-through fraction was collected.

The

column was washed with 16 mL of lysis buffer, and the fraction was collected.
Finally, the fusion protein was eluted from the column in 9 aliquots of 0.5 mL of
lysis buffer containing an increasing concentration of maltose (1 mM for fraction
1, 2 mM for fraction 2, 5 mM for fraction 3, and 10 mM for fractions 4-9). All
purification fractions were analyzed by SDS-PAGE electrophoresis to determine
the purity of the expressed protein. Fractions containing significant impurities
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were discarded, and purified protein was combined and dialyzed in 1 L of
labeling buffer (20 mM HEPES, pH 7.2) overnight at 4 °C.
Labeling HbpR-A-MBP with IAEDANS.

The thiol-reactive, environmentally-

sensitive fluorophore IAEDANS was used for protein labeling.

Protein

modification was carried out according to the Invitrogen Molecular Probes
handbook for thiol-reactive probes.

Briefly, the protein was denatured and

possible disulfide bonds were reduced by reacting 3.0 mL of the protein in
labeling buffer containing 1 mM TCEP and 6 M urea for 2 h at 4 °C with stirring.
Following this reaction, 10 µL of a 2.3 x 10-2 M stock of IAEDANS in DMSO was
added to the same vial, resulting in a 10-fold molar excess of IAEDANS with
respect to the number of cysteines present. This mixture was allowed to react in
an amber glass vial in the dark overnight at 4 °C with stirring. Following the
labeling reaction, the solution was dialyzed extensively at 4 °C to remove any
free IAEDANS from solution and to gradually remove urea and allow protein
refolding. The reaction solution was placed inside of a 10,000 molecular weight
cut-off, 10 mL dialysis cassette and dialyzed in an initial dialysis buffer (20 mM
HEPES, 2 M urea, 0.2 mM EDTA, pH 7.4) for 7 h at 4 °C with mixing in the dark.
Following this, consecutive buffer changes were performed by removing half of
the dialysis buffer and replacing with dialysis buffer with no urea, halving the
previous urea concentration. Each dialysis step was carried out for at least 4 h.
This was repeated 5 times, and then a final dialysis was carried out replacing the
entire volume of dialysis buffer. The thoroughly dialyzed protein solution was
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then removed from the dialysis cassette, placed in an amber glass vial, and
stored at 4 °C.
Fluorescence Assays of OH-PCBs in Buffer.

For fluorescence assays in

buffer, stock solutions of selected OH-PCBs were prepared at a concentration of
1 x 10-2 M in DMSO. From these stock solutions, standards were prepared by
serial dilution in DMSO resulting in a range of concentrations from 1 x 10-2 M to 1
x 10-8 M. Using these DMSO standards, assay standards were prepared by
diluting each DMSO standard 1:10 into assay buffer (10 mM HEPES, pH 7.5),
resulting in assay standards with a range of concentrations from 1 x 10-3 M to 1 x
10-9 M. An assay blank was also prepared by preparing a 10% (v/v) solution of
DMSO in assay buffer. To perform assays of the compounds, 180 µL of the
HbpR-A-MBP-IAEDANS solution at a concentration of 1 x 10-7 M was mixed with
20 µL of assay standards, as well as a blank sample, in triplicate.

The

fluorescence was measured using a BMG Labtech Polarstar Optima microtiter
plate fluorimeter.

Data were plotted using GraphPad Prism 5.0 (GraphPad

Software, San Diego, CA) with a three-parameter sigmoidal curve fitting
equation, and apparent binding constants were derived from this equation.
Detection limits were determined as the concentration tested that produced a
signal intensity that is at least 3 standard deviations above the blank signal.
Fluorescence Assay of 2-Hydroxy-3’,4’-dichlorobiphenyl in Human Serum.
The assay of 2-hydroxy-3’,4’-dichlorobiphenyl was carried out in human serum.
The procedure was carried out as above for the preparation of standards, except
that in the preparation of assay standards, purchased human serum was used
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instead of buffer.

The resulting serum samples contained the OH-PCB in a

concentration range of 1 x 10-3 M – 1 x 10-9 M. Using these standards, the assay
procedure above was followed precisely.

RESULTS AND DISCUSSION
HbpR is a member of the XylR/DmpR subclass of the NtrC family of
regulatory proteins from bacteria.[146] This family of proteins typically contains
four distinct domains (figure 3.1). The effector binding domain, or A-domain,
interacts directly with an effector molecule and begins a drastic conformational
change, which is relayed to the rest of the protein through a helix linker region in
the B-domain. The conformational change is then translated to the C-domain,
whose ATP-ase activity is triggered, which then recruits the σ54 RNA polymerase.
Simultaneously, the DNA-binding D-domain undergoes a conformational change,
which triggers its release from the operator region of the DNA resulting in
expression of genes under the control of the associated promoter.[146] In the
subclass of proteins encompassing XylR, DmpR, and HbpR, the effector
molecule is aromatic, and it has been demonstrated that the isolated A-domain
binds to its aromatic effector molecule in vitro.[147]
Members of this class of proteins are particularly difficult to express,
purify, and stabilize in solution, and as a result structural information for members
of this class of proteins has been difficult to acquire.[145, 148] Any structural
information that has been obtained thus far is the result of modeling the structure
of these proteins using as a template other proteins, which are very distantly
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related and lack a high degree of homology.[145, 148]

This lack of specific

information on the overall protein structure, coupled with the lack of detailed
information on the conformational change that occurs upon effector molecule
binding makes it nearly impossible to rationally-design a protein that will generate
a measurable change in signal upon analyte binding.
As an alternative, we have taken a shot-gun approach by attaching a
fluorophore simultaneously to cysteines present in HbpR. Several strategies for
expressing and purifying in significant quantities either the entire HbpR protein,
or the isolated A-domain, HbpR-A were attempted. Initially, the genes for the
expression of HbpR and HbpR-A were cloned into the expression vector
pRSETA. This expression system is designed to express the protein with an Nterminal histidine tag. This system yielded small amounts of insoluble protein for
both HbpR and HbpR-A; subsequent attempts to denature and refold the protein
were unsuccessful (data not shown). In order to improve protein solubility, we
cloned the genes for both the full-length and truncated protein into the expression
vector pMAL-p4E, which expresses the protein as a C-terminal fusion to MBP.
Maltose binding protein possesses exceptional solubility and often confers this
property upon its protein fusion partner. Indeed, when expressed as a fusion we
were able to obtain soluble, purified HbpR-A-MBP.

The HbpR-MBP fusion

protein was insoluble upon expression. Attempts to cleave HbpR-A from MBP
and purify isolated HbpR-A were also unsuccessful, as the protein immediately
precipitated. For these reasons, this work focuses on the use of the HbpR-AMBP fusion protein.
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Extensive characterization of HbpR has been carried out previously. The
selectivity of HbpR has been well-defined by initial work carried out by Jaspers et
al. and expanded by our previous work.[4, 146]

HbpR shows the greatest

response to its native effector, 2-hydroxybiphenyl, but also has been shown to
respond to some structurally related compounds such as 2,2’-dihydroxybiphenyl,
2-aminobiphenyl, 2-hydroxydiphenylmethane and many OH-PCBs. However, all
previous work with this protein was accomplished in a cell-based sensing
approach.

The isolated protein has never been directly used in vitro to

investigate the binding of any of these molecules.
The purified fusion protein was labeled with an environmentally-sensitive
fluorophore, IAEDANS.

An initial assay using this protein, HbpR-A-MBP-

IAEDANS, with standards of the compound 2-hydroxy-3’,4’-dichlorobiphenyl in
buffer demonstrated that the protein did indeed respond in a dose-dependent
manner (figure 3.2), with a limit of detection of 1.0 x 10-7 M. The assay for 2hydroxy-3’,4’-dichlorobiphenyl was also carried out in spiked human serum. A
concentration-dependent response was observed in both sample matrices,
although the blank-subtracted fluorescence intensity was slightly lower in serum
samples, and the detection limit was an order of magnitude higher. This could be
because the analyte may associate with proteins in serum making it less
available to the protein-based sensor. However, the ability to detect OH-PCBs
directly in serum with no sample pretreatment is a significant improvement over
current detection methods.
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Figure 3.2. Dose-response curves for 2-Hydroxy-3’,4’-dichlorobiphenyl in
buffer and spiked human serum. The assay was carried out by mixing 20 µL
of each standard in either buffer (■) or serum (●) with 180 µL of 1 x 10-7 M HbpRA-MBP-IAEDANS and measuring immediately after mixing. The samples were
prepared in triplicate, the results were averaged, and the signal of the blank was
subtracted. The results were fitted with a sigmoidal response curve. Error bars
denote +/- one standard deviation.
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To investigate the effect of incubation time on assay performance, the
signal from a single microtiter plate assay was measured immediately after
addition of the analyte.

Additional fluorescence measurements of the same

microtiter plate were performed at 15 min, 45 min, and 105 min. While there was
a gradual decrease in the total fluorescence intensity of the measurements with
time, the detection limit and dynamic range were not improved at longer
incubation times (Figure 3.3). For this reason, all measurements were performed
with no additional incubation time.
In order to investigate the response characteristics of the biosensing
system, additional assays were carried out for the detection of other OH-PCBs as
listed in table 3.1. The biosensing system responded to most of the OH-PCBs
tested, with the exception of 2-hydroxy-3',5,5'-trichlorobiphenyl and 2,3dihydroxy-3',4'-dichlorobiphenyl. In previous work in our laboratory, our wholecell sensing system seemed to respond to the former. It is unclear why the
isolated protein would fail to respond to this compound. However, our whole-cell
sensing system failed to respond to any dihydroxy compounds, so it is
unsurprising that the isolated protein shows no response to the latter. Since in
our protein biosensing system, HbpR-A is expressed as a fusion to MBP, which
contains one cysteine that could be modified with IAEDANS, we conducted the
assay using MBP-IAEDANS with 2-hydroxybiphenyl to confirm that no response
was observed from MBP alone (data not shown). This was done to ensure that
the response we were observing was due to HbpR-A and not to MBP.
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Figure 3.3. Time study of 2-Hydroxy-2’,3’,5’,6’-tetrachlorobiphenyl in buffer.
The assay was carried out by mixing 20 µL of each standard in buffer with 180
µL of 1 x 10-7 M HbpR-A-MBP-IAEDANS and measuring immediately (●), after
45 min (■), and after 105 min (▲). The samples were prepared in triplicate, the
results were averaged, and the signal of the blank was subtracted. Error bars
denote +/- one standard deviation.

84

Detection limits for the compounds assayed ranged from 1 x 10-8 M to 1 x 10-6 M,
and the dynamic range varied from one to three orders of magnitude (Table 3.1).
The percent relative standard deviation (%RSD) was calculated for each of the
data points for all of the compounds as an evaluation of intra-assay
reproducibility. The %RSD ranged from 0.01 to 10.8. Additionally, the %RSD
was calculated using data from repeated assays of the same compound, 2hydroxy-3’,4’-dichlorobiphenyl in order to evaluate inter-assay variability and
found to range from 1.1 to 2.3.

These data suggest that the assay is

reproducible.
It is hypothesized that the differing response to various OH-PCBs is due to
structural differences between the molecules, which would affect their interaction
with the binding pocket of HbpR-A. Without the availability of detailed structural
information of the protein only inferences can be made to explain the variations in
response. To gain some insight into the observed variation in the response to
different compounds, correlation analysis was performed on the data. Spearman
correlation analyses were performed on the basis of a number of characteristics
that differentiate OH-PCB congeners (Table 3.2).

First, the dihedral angle

between the two aromatic rings of each molecule was calculated.

This was

accomplished by modeling the energy-minimized 3D structure of the compounds
using Chem3D Pro 12.0 (CambridgeSoft, Cambridge, MA) The dihedral angle
reflects the planarity of each molecule. In general, substitutions in the orthopositions on each ring contribute to a less planar conformation for the OH-PCBs.
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Table 3.2. Molecular characteristics of selected OH-PCBs
Compound
2,3-Dihydroxy-3',4'-dichlorobiphenyl
2-Hydroxy-2',3',4',5,5'-pentachlorobiphenyl
2-Hydroxy-2',3,4',5',6-pentachlorobiphenyl
2-Hydroxy-2',3',4',5-tetrachlorobiphenyl
2-Hydroxy-2',3',5',6'-tetrachlorobiphenyl
2-Hydroxy-2',4',5,6'-tetrachlorobiphenyl
2-Hydroxy-2',4',6-trichlorobiphenyl
2-Hydroxy-3',4'-dichlorobiphenyl
2-Hydroxy-3',5,5'-trichlorobiphenyl
4-Hydroxy-2',3,4',5-tetrachlorobiphenyl
4-Hydroxy-2',3',5-trichlorobiphenyl
4-Hydroxy-2',4',6'-trichlorobiphenyl
4-Hydroxy-3,3',4',5-tetrachlorobiphenyl
4-Hydroxy-3,3',5'-trichlorobiphenyl
4-Hydroxy-3,5-dichlorobiphenyl

Volume (Å3)
171.3
209.3
210.6
195.0
197.7
197.6
182.5
164.9
179.1
193.4
179.2
180.6
192.2
178.6
163.6
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logP
4.25
6.62
6.62
6.01
5.59
5.64
5.38
4.75
5.40
6.01
5.38
4.78
6.01
5.40
4.73

Dihedral Angle (°)
22
42
56
41
60
57
54
21
22
29
31
44
1
0
0

The solvent exclusion volume that each molecule would be expected to occupy
was also calculated using Chem3D Pro 12.0.

This value may influence the

affinity to the binding pocket, as molecules that are either too large or too small
would not be expected to bind well. Lastly, the partition coefficient, logP, which is
a reflection of the hydrophobicity of each molecule, was calculated using
ChemDraw Ultra 12.0 (CambridgeSoft, Cambridge, MA).

These values are

predicted using a fragmentation method based on atomic contributions from a
large reference set of molecules by least squares analysis. Since the effector
molecules that bind to HbpR are hydrophobic, it is expected that the binding
pocket of HbpR is a hydrophobic binding pocket located on the interior of the Adomain.

Additionally, binding pockets located in the interior of proteins are

typically a hydrophobic environment.

For this reason, the hydrophobicity of

different congeners may affect the binding interaction.
Correlation analyses for each of these parameters were carried out with
respect to the detection limits and apparent KD values observed in the assay
data.

There was no significant correlation calculated between either the

detection limits or apparent KD values and the dihedral angles or the molecular
volumes.

However there was a slight correlation (r = 0.5885, p = 0.0344)

between the detection limits and the partition coefficients and an even stronger
correlation (r = 0.7406, p = 0.0038) between the apparent KD values and the
partition coefficients (figure 3.4). This would suggest that as the hydrophobicity
of the molecules increases so do both the detection limit and the apparent KD
value. A possible explanation of this behavior is that the position of the hydroxy
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Figure 3.4.

Correlation analysis of logP values and apparent binding

affinities. Apparent binding affinities, KD, were calculated by GraphPad Prism
5.0 software from sigmoidal response curves obtained from the assay of each
compound.

Values of logP were obtained using ChemDraw Ultra 12.0.

A

Spearman correlation analysis was performed between the two parameters using
GraphPad Prism 5.0 software. The calculated correlation value was 0.7406 (p =
0.0038).
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functionality is important and determines to some extent how HbpR interacts with
the effector molecules.

There may be one or more hydrophilic amino acids

present within the binding pocket of HbpR that participate in hydrogen-bonding
interactions with the hydroxy-group. Interestingly it appears that it is not the
position of the chlorine substituents from various OH-PCBs that determines
strength of interaction through steric hindrance, but rather the relative
hydrophobicity of the OH-PCBs. This suggests that the binding pocket may be
large and hydrophobic and as such be able to accommodate a wide range of
structurally related compounds. To be able to ascertain this with a high degree
of confidence would require the availability of the three-dimensional structure of
HbpR.

CONCLUSION
We have developed a protein-based sensing system for the detection of
OH-PCBs by the covalent attachment of the fluorophore IAEDANS to cysteines
present in the effector binding domain of the transcriptional regulatory protein
HbpR. We have demonstrated the dose-dependent response in buffer as well as
in a sample matrix of human serum. This biosensing system responds broadly to
most OH-PCBs tested resulting in detection limits as low as 1 x 10-8 M, which
should enable its application as a rapid, cost-effective, high-throughput screening
method for large numbers of samples suspected of containing OH-PCBs. This
should lead to the identification of positive samples to be subjected to a more indepth analysis by other analytical methods such as GC-MS. Ongoing structural
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studies of HbpR should eventually provide more detailed structural information,
which will provide for the rational design of the protein to improve its response
characteristics and allow for the development of a biosensing system with more
desirable properties, such as, improved detection limits, selectivity, and response
to more highly chlorinated OH-PCBs.
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CHAPTER FOUR
ENGINEERING GLUCOSE RECOGNITION PEPTIDES FROM NATURE:
SELECTIVE AND SENSITIVE BIOSENSORS FOR GLUCOSE

INTRODUCTION
The development of reliable, low cost technologies for glucose sensing
has been an active field of research since the first glucose biosensing device was
proposed in 1962.[96, 149] While recent generations of these devices have seen
improvements in performance, the basic principles of the technology have
remained almost identical. Current-generation commercially available glucose
meters measure glucose by electrochemical methods based on the enzymes
glucose oxidase (GOx) or glucose-1-dehydrogenase (GDH).[149]

These

electrochemical methods suffer from some significant drawbacks including
hematocrit dependence, interference from other electrochemically active
molecules, hypoxemia, or hypotension.[149] Lack of electrochemical selectivity
is especially troublesome, as the list of potentially interfering compounds includes
molecules commonly found in blood such as acetaminophen, salicylic acid,
ibuprofen, ascorbic acid, etc.[96, 150]
To overcome the disadvantages of electrochemical methods for glucose
sensing, methods based on alternative technologies have been proposed and
are currently being evaluated.

To that end, the design and development of

reagentless optical sensing strategies that are sensitive, selective, reproducible,
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accurate, rugged, and capable of glucose detection in the physiological
concentrations and conditions is an active field of research.

Among these

methods are fluorescence-based,[89, 151, 152] fluorescence resonance energy
transfer (FRET)-based,[151, 152] and bioluminescence-based[72] methods. In
each of these cases, the glucose/galactose binding protein (GBP) (Figure 4.1)
from Escherichia coli is employed as the biological recognition element. GBP is
a well-studied periplasmic binding protein consisting of 309 amino acids, which
undergoes a hinge-motion conformational change upon binding glucose or
galactose. As outlined in the examples mentioned above, this conformational
change has been exploited in a variety of ways to produce a measurable optical
signal in response to glucose. As a result of these methods relying on an optical
response, many of the drawbacks of electrochemically-based detection of
glucose, such as interference from other molecules are circumvented.
While biosensing systems based upon GBP address some of the shortcomings
of electrochemical-based systems, the relatively low dissociation constant (KD) of
GBP (in the micromolar range) compared to the physiological concentration of
glucose (in the millimolar range) constrains GBP’s widespread implementation
into commercial devices.

Efforts to alter the binding affinity of proteins by

affecting changes in the amino acid sequence have included site-directed
mutagenesis,[151, 153] random mutagenesis,[154] and DNA shuffling.[155]
These efforts have resulted in proteins with affinities shifted to the millimolar
range, however the selectivity toward glucose against other sugars and
glycosylated moeities has not been fully determined. These approaches may
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Figure 4.1. Protein structures for native GBP and tGRPs. Native GBP (a.) is
shown with galactose in the ligand-binding pocket and calcium (shown in green)
present in the calcium-binding pocket (PDB ID: 1GLG). In (b.), the binding
pocket is magnified showing the amino acids involved in hydrogen bonding with
glucose as well as Cys152. tGRP1 (b.), tGRP2 (c.), and tGRP3 (d.) are shown
with truncated areas of the protein in red.
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significantly alter the inherent selectivity of the protein, as they involve
introducing significant changes into the binding pocket; thus the applicability of
these systems for glucose sensing may be somewhat compromised.
In this work, we hypothesize that by rationally engineering the protein to
truncate portions of GBP, we can construct truncated glucose recognition
peptides (tGRPs), which maintain the wild-type GBP’s response to glucose while
altering the dissociation constant of the protein by affecting the overall folding
and structure of the protein. In the design of these proteins, it is important to
maintain much of the hydrogen-bonding network that is responsible for the direct
interaction with glucose, as well as the hinge region connecting the two lobes, so
that the integrity of the binding is preserved. Herein, we present a series of
newly designed tGRPs, their characterization, and their use in glucose sensing.
EXPERIMENTAL PROCEDURES
Reagents.

All oligonucleotide primers were purchased from Operon

Biotechnologies (Huntsville, AL). Phusion DNA polymerase was purchased from
New England Biolabs (Ipswich, MA). 2-Amino-2-hydroxymethyl-propane-1,3-diol
(Tris-base), β-mercaptoethanol, bovine serum albumin (BSA), dimethyl sulfoxide
(DMSO), calcium chloride (CaCl2), ampicillin sodium salt, tetracycline, ethidium
bromide,

agarose,

2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic

acid

(HEPES), and D-glucose, sucrose, and lactose, and D-galactose were obtained
from

Sigma-Aldrich

(St.

Louis,

MO).

Glycine,

sodium

chloride,

ethylenediaminetetraacetic acid (EDTA), and Luria-Bertani (LB) broth and agar,
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were purchased from Fisher Scientific (Fair Lawn, NJ). Methanol, acetic acid,
sodium phosphate dibasic, sodium phosphate monobasic, glycerol, and
bromophenol blue were purchased from VWR (Bridgeport, NJ). Imidazole and
maltose were purchased from J.T. Baker (Phillipsburg, NJ). Isopropyl β-D-1thiogalactopyranoside (IPTG) and dithiothreitol (DTT) were purchased from Gold
Biotechnology (St. Louis, MO). Sodium dodecyl sulfate was ordered from Curtin
Matheson (Houston, TX). The Bradford protein assay kit was purchased from
Biorad (Hercules, CA).

Ni-NTA agarose resin, QIAquick gel purification kit,

QIAprep DNA isolation kit, and the pQE70 vector were purchased from Qiagen
(Valencia, CA). TOP10F’ cells, Tris-Glycine SDS PAGE gels, 7-diethylamino-3((((2-maleimidyl)ethyl)amino)carbonyl)coumarin

(MDCC),

Mark12

protein

standard, and 1 kb DNA standard were purchased from Invitrogen (Carlsbad,
CA).

Three thousand five hundred MWCO Slide-A-Lyzer 3-12 mL dialysis

cassettes were purchased from Pierce (Rockford, IL).

T4 DNA ligase, SphI

restriction enzyme and BglII restriction enzyme were purchased from Promega
(Madison, WI).
Apparatus.
Eppendorf

Polymerase chain reactions (PCR) were performed using an
Mastercycler

Personal

Thermocycler

(Hauppauge,

NY).

Electrophoresis of DNA was carried out using an FB105 Fischer Biotech
Electrophoresis Power Supply (Pittsburg, PA). DNA gels were visualized using a
UV Transilluminator platform from UVP (Upland, CA).

Optical density

measurements were obtained using a Spectronic 21D from Milton Roy (Ivy Land,
PA). Cells were lysed using a 550 Sonic Dismembrator from Fisher Scientific
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(Pittsburg, PA). Proteins were expressed by incubating bacteria at 37 oC on a
Forma Scientific Orbital Shaker (Fairlawn, NJ). All centrifugations were carried
out using a Beckman J2MI centrifuge (Palo Alto, CA). Proteins were visualized
by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using
Invitrogen 10-20% Tris-glycine gels in an Invitrogen X Cell Sure Lock Mini Cell
(Carlsbad, CA).

Fluorescence measurements were obtained using a

QuantaMaster 40 Spectrofluorometer from PTI (Birmingham, NJ).

Circular

dichroism measurements were taken using a Jasco J-810 Spectropolarimeter
(Easton, MD). DNA sequencing was performed by the Advanced Genetic
Testing Center at the University of Kentucky.
Cloning of Truncated Glucose Recognition Peptides (tGRPs). To prepare
tGRPs, various segments of the full-length glucose binding protein (GBP)
containing a mutation introducing a unique cysteine in place of histidine at
position 152 from Escherichia coli (E. coli) were amplified by PCR and ligated
into the expression vector pQE70. Specifically, gene fragments were amplified
corresponding to amino acids 14-296 (tGRP1), 14-256 (tGRP2), and 87-271
(tGRP3) of the native sequence.

For the amplification of tGRP1, primers

tGBP(14-)fwd [5’-GGTGGTGCATGCGCGATAACTTTATGTCTGTAGTGCGG-3’]
and tGBP(-296)rev [5’-GGTGGTAGATCTAACATAAGGTACGCGGACCAC-3’]
were used. For the amplification of tGRP2, primers tGBP(14-)fwd and tGBP(256)rev [5’-GGTGGTAGATCTGTTCAGTACGGTGCCCGCCAG-3’] were used.
For

the

amplification

of

tGRP3,

primers

tGBP(87-)fwd

GGTGGTGCATGCGCGTGGTTTTCTTCAACAAAGAACCG-3’]
96

and

[5’tGBP(-

271)rev

[5’-GGTGGTAGATCTGTTTTTCGCCAGATCAAAGGTCGC-3’]

were

used. PCR was carried out using Phusion High-Fidelity DNA Polymerase. PCR
conditions consisted of an initial denaturation period of 30 s at 98 °C. Next, 30
cycles of 98 °C for 30 s, 70 °C for 30 s, and 72 °C for 60 s followed by a final
elongation period of 72 °C for 5 min were carried out. The resulting reaction
products were analyzed by tris-acetate-EDTA (TAE) 1% agarose gel
electrophoresis, and the appropriate DNA fragments (861 bp for tGRP1, 741 bp
for tGRP2, and 567 bp for tGRP3) were excised from the gel and purified using
the QIAquick gel extraction kit.
The DNA fragments tGRP1, tGRP2, and tGRP3 along with expression
vector pQE70 were digested with restriction enzymes BglII and SphI.

The

resulting products were analyzed by TAE 1% agarose gel electrophoresis,
excised from the gel, and purified using the QIAquick gel extraction kit. A gel
slice of digested pQE70 was co-purified in each separate tube containing tGRP1,
tGRP2, and tGRP3 allowing the vector and insert to be eluted from the
purification column simultaneously. To the eluted DNA, T4 DNA ligase and T4
DNA ligase buffer (10x) were added, and the ligation reaction was allowed to
proceed overnight at room temperature. The ligated DNA was transformed into
TOP10F’ cells. Plasmid DNA was isolated from overnight cultures of selected
transformants and analyzed for the presence of the desired DNA fragments by
digestion with BglII and SphI. DNA sequencing was also performed to confirm
the correct DNA sequence.
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tGRPs Expression and Purification.

Plasmids tGRP1 and tGRP2 were

transformed into TOP10F’ chemically-competent cells. For protein expression,
cells were grown overnight at 37 °C with shaking in 3 mL of LB broth containing
ampicillin (100 µg/mL) and tetracycline (12.5 µg/mL) for selection. The following
day in a 1 L flask, 500 mL of LB broth containing ampicillin (100 µg/mL) and
tetracycline (12.5 µg/mL) was inoculated with the overnight culture and grown at
37 °C with shaking at 250 rpm to an OD600 of 0.4-0.5. Protein expression was
then induced with IPTG at a final concentration of 1.0 mM. The expression
culture was grown overnight at room temperature with shaking.
For protein purification, the culture expressing the desired proteins was
centrifuged to a pellet at 12000 x g for 20 min at 4 °C, and the supernatant was
removed and discarded. The bacterial cell pellet was resuspended in 15 mL lysis
buffer (50 mM NaH2PO4, 30 mM NaCl, 10 mM imidazole, pH 8.0) and lysed by
sonication on ice using a programmed cycle of 10 s on, 10 s of, for 10 min total.
The cell debris was pelleted by centrifugation 12000 x g for 20 min at 4 °C, and
the resulting crude protein-containing cell-extract was removed to a separate
culture tube. To the crude extract, 1.0 mL of Ni-NTA resin was added and mixed
at 4 °C for 1 h. The solution was then added to a gravity-flow column, and the
flow through was collected. The resin was washed with 20 mL of wash buffer (50
mM NaH2PO4, 30 mM NaCl, 20 mM imidazole, pH 8.0), and the wash fraction
was collected. Purified protein was eluted from the column in 1.0 mL aliquots of
elution buffer (50 mM NaH2PO4, 30 mM NaCl, 250 mM imidazole, pH 8.0). All
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collected fractions were analyzed by SDS-PAGE electrophoresis, and fractions
containing purified protein were combined and stored at 4°C.
tGRPs Modification with Fluorophore. Purified proteins were reacted with an
excess of DTT to reduce possible disulfide bonds between two molecules of
tGRP. Excess DTT was removed by dialysis in 3500 MWCO dialysis cassettes
in dialysis buffer (10 mM HEPES, 0.2 mM CaCl2, pH 8.0). The dialyzed protein
was reacted with a 10-fold molar excess of MDCC dissolved in DMSO, using
manufacturer’s instructions. The labeling reaction was carried out overnight at 4
°C in an amber glass vial, protected from light. Following the labeling reaction,
the protein was extensively dialyzed against dialysis buffer (as above) to remove
any excess MDCC. Labeled proteins were stored at 4 °C, protected from light.
Assay of Glucose with MDCC-labeled tGRPs. For the glucose assay, MDCClabeled protein was used at a final concentration of 1 x 10-7 M in assay buffer (10
mM HEPES, 0.2 mM CaCl2, pH 8.0). Glucose standards were freshly prepared
in assay buffer by serial dilution using a freshly prepared 0.1 M glucose solution.
For the assay, 180 µL of the labeled protein solution was added to 20 µL of each
standard, as well as a blank, in triplicate and mixed gently and thoroughly.
Fluorescence was measured immediately in a 200 µL quartz microcuvette.
MDCC was excited at a wavelength of 419 nm, and fluorescence emission
collected at 466 nm. Instrument slit widths were set to 4 nm, step size was 0.5
nm, integration time was 0.1 s. Fluorescence at 466 nm was graphed versus
glucose concentration and analyzed using GraphPad Prism 5.0 software.
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Measurement of Far- and Near-UV Circular Dichroism Spectra. Far-UV and
near-UV circular dichroism spectra were collected for tGRP1 and tGRP2 in both
the presence and absence of glucose.

Briefly, protein concentration was

determined according to the method by Greenfield et al.[156] Proteins were
dialyzed in CD buffer (10 mM phosphate, 0.2 mM CaCl2, pH 7.5).

Protein

samples were prepared at a concentration of 0.2 mg/mL with and without the
presence of 100 mM glucose in CD buffer for far-UV experiments and 1.0 mg/mL
for near-UV experiments. Blank solutions consisting of CD buffer were prepared
with and without 100 mM glucose. Spectra were collected using a Jasco J-810
spectropolarimeter.
For far-UV experiments, spectra were collected at room temperature from
200-260 nm, the data pitch was set to 0.5 nm, scanning mode was set to
continuous, scan speed was 20 nm/s, response was set to 8 s, bandwidth was 1
nm, and accumulations was set to 3. A quartz CD cuvette with a pathlength of
0.1 cm was used. Near-UV experiments were carried out at room temperature in
a quartz cuvette with a 1.0 cm pathlength.

Scans were performed with the

settings mentioned above, however the wavelength range was 250-350 nm.
Data for corresponding blanks were subtracted from each sample, and the
results were converted to molar ellipticity. Spectra were created by plotting molar
ellipticity versus wavelength using GraphPad Prism 5.0 software.
Determination of Protein Thermal Stability. The melting temperature of each
of the tGRPs was determined by monitoring circular dichroism at a wavelength of
222 nm.

Samples were prepared as described for the far-UV experiments.
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Settings were the same as above. The temperature range was set from 10-90
°C at a slope of 2 °C/min.

Data were plotted versus temperature using

GraphPad Prism 5.0 software and normalized with respect to the signal at 70 °C.

RESULTS AND DISCUSSION
The glucose binding protein has been studied extensively as a possible
sensing component of future generation of devices for the continuous, real-time
monitoring of glucose for the management of diabetes.[72, 89, 151, 154]
However, it has been noted that the native form of the protein has a binding
affinity in the micromolar range, which is too low to be useful at physiologicallyrelevant glucose concentrations, which range from 2-20 millimolar. By truncating
the structure of GBP, we hypothesize that the resulting perturbation in the
structure and folding of the protein will result in an altered affinity for glucose.
Truncation, like random and site-directed mutagenesis, may alter the stability,
folding, activity, and binding interactions of a protein. It has been shown that
truncated proteins can exhibit altered activity and binding affinities.[157, 158]
Previous work has determined the binding constant of native GBP for
glucose to be 0.2 µM.[89] To investigate the effect of truncating GBP on the
binding affinity and stability of the protein, three truncated versions of GBP were
engineered. These three proteins, tGRP1, tGRP2, and tGRP3 consist of amino
acids 14-296, 14-256, and 87-271, respectively, of native GBP (Figure 4.1). In
order to maintain activity toward glucose, selectivity against other sugar
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molecules, and the ability to undergo the correct conformational change, the
native structure was truncated in such a way that most of the amino acids
involved in hydrogen-bonding interactions within the binding site were
maintained. Native GBP interacts with glucose through a network of hydrogenbonding interactions involving Asp14, Asn91, His152, Asp154, Arg158, Asn211,
Asp236, and Asn256 (Figure 4.1).[159] tGRP1 and tGRP2 were engineered to
include all amino acids listed above. tGRP1 included all amino acids through
residue 296 in order to maintain all three strands of the hinge region of the
protein structure. In the design of tGRP2, all amino acids located after residue
256 were removed, thus maintaining all hydrogen-bonding amino acids as well
as two of the three strands composing the hinge region. In the design of tGRP3,
much of one lobe of the protein, one strand of the hinge region, and one amino
acid from the binding pocket were removed. The three different proteins were
expressed in E. coli and chemically modified via site-selective labeling of a
unique Cys residue with a fluorescent coumarin probe, namely MDCC.
The truncated proteins were characterized in terms of their binding ability
to glucose and to other sugers. Upon glucose binding, the fluorescence emission
from the MDCC-labeled tGRPs was quenched.

We hypothesize that in the

absence of glucose (when the protein structure is more open) the fluorescent
probe MDCC assumes a position within the glucose binding pocket. However,
when glucose binds, MDCC is displaced from this position causing a change in
fluorescence. Native GBP exhibits a KD of 0.2 µM. It was found that as the
protein was increasingly truncated, the apparent KD increased, indicating a
102

decreasing affinity for glucose (Figure 4.1) to the point that tGRP3 showed no
response to glucose (data not shown). In the structure of native GBP, eight
amino acids are directly involved in hydrogen-bonding as a first-shell type of
interaction with glucose, and, in addition, ten more amino acids interact with the
first-shell amino acids to stabilize their structure around the sugar ligand.[159]
While both tGRP1 and tGRP2 maintain all of the first-shell interacting amino
acids, part of their second-shell amino acids was removed.

Specifically, in

tGRP1 and tGRP2 one and four second-shell amino acids were removed
respectively.

As more of these stabilizing, second-shell amino acids are

removed, it is likely that the hydrogen-bonding interactions with glucose become
disrupted, thus resulting in an increased KD of 75 µM for tGRP1 and 0.25 mM for
tGRP2 (Figure 4.2).
Disrupting the first- and second-shell amino acids may also affect the
selectivity of the proteins, causing them to respond to sugar molecules other than
glucose and galactose. As the overall structure becomes less stable, it is
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Figure 4.2. Normalized fluorescence response curve for tGRP1 and tGRP2.
The glucose-response curve for tGRP1 and tGRP2 labeled at position 152 (with
respect to native GBP) with MDCC. MDCC-labeled protein was used at a final
concentration of 1 x 10-7 M in buffer (10 mM HEPES, 0.2 mM CaCl2, pH 8.0).
Glucose standards were prepared in buffer by serial dilution from a fresh 0.1 M
glucose solution.

For the assay, 180 µL of the labeled protein solution was

added to 20 µL of each standard, as well as a blank, in triplicate and mixed
gently and thoroughly and fluorescence was measured immediately. Data points
represent the average of blank-subtracted triplicate samples. The apparent KD
for tGRP1 is 7.5 x 10-5 M and for tGRP2 is 2.5 x 10-4 M. The dynamic range for
tGRP1 and tGRP2 is 1 x 10-3 M – 1 x 10-6 M and 1 x 10-2 M – 1 x 10-5 M
respectively. Error bars denote +/- one standard deviation.
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possible the binding pocket may become more flexible and able to accommodate
other similarly-shaped ligands.

To investigate this, a selectivity study with

MDCC-labeled tGRPs was carried out with a variety of physiologically-relevant
sugar molecules (Figure 4.3). As with native GBP, tGRPs responded best to
glucose and to a lesser degree to galactose. None of the other sugar molecules
showed a significant response.
To investigate whether the overall structural stability of the tGRPs was
altered, the thermal stability of each tGRP was determined by circular dichroism
(CD) spectroscopy. Protein thermal stability is an important consideration when
developing protein-based sensors that will be used for extended periods of time
at human body temperatures. Improved thermal stability will increase the lifetime
of the sensor allowing for long-term, reproducible glucose determination. Native
GBP has a melting temperature (Tm) of 66.9 °C in the absence of glucose and
70.2 °C in the presence of glucose.[160] Truncating the native structure had a
significant effect on the thermal stability (Figure 4.4).

In the absence and

presence of glucose, tGRP1 was found to have a Tm of 39.7 °C and 44.2 °C
respectively. The corresponding Tm values for tGRP2 were 37.3 °C and 43.2 °C.
Since tGRP3 showed no glucose response, it was not characterized further. This
drastic loss in thermal stability indicates significant structural changes in the
protein structure that result from truncation, which is manifested as an increase in
dissociation constants for the ligand.
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Figure 4.3. Selectivity study of tGRP1 and tGRP2 with selected sugars.
Samples for each sugar were prepared at a concentration of 100 mM in buffer
and the experiment was carried out as described in Figure 1.

The total

fluorescence signal is quenched approximately 80% by glucose and 40% from by
galactose. There was no significant response observed to maltose, sucrose,
fructose, or lactose. Error bars denote +/- one standard deviation.
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Figure 4.4. Thermal denaturation curves for tGRP1 (a.) and tGRP2 (b.) in
the presence and absence of 100 mM glucose. Proteins were prepared at a
concentration of 0.2 mg/mL in CD buffer (10 mM phosphate, 0.2 mM CaCl2, pH
7.5) both in the absence of glucose and in the presence of 100 mM glucose. CD
was monitored at 222 nm as the temperature was increased from 10 to 70 °C at
a rate of 2 °C per min. The melting temperature for tGRP1 was 39.7 °C in the
absence of glucose and 44.2 °C in the presence of glucose.

The melting

temperature for tGRP2 was 37.3 °C in the absence of glucose and 43.2 °C in the
presence of glucose.
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a.

b.

Figure 4.5. Far-UV (a.) and near-UV (b.) CD absorbance of tGRP1 in the
presence and absence of 100 mM glucose.
Protein solutions and corresponding blanks were prepared at a concentration of
0.2 mg/mL in CD buffer in the presence and absence of glucose as described in
Figure 4.3. The CD absorbance was measured from 260-200 nm at a pitch of
0.5 nm in continuous scanning mode at a scan speed of 20 nm/s for far-UV and
350-250 nm at a pitch of 0.5 nm and scan speed of 20 nm/min for near-UV
measurements. Three accumulations were averaged for each sample at room
temperature. The response for each blank was subtracted from the response for
the corresponding sample and the resulting spectra are shown.characteristics of
the proteins.
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Further characterization of the tGRPs by circular dichroism revealed that, similar
to native GBP, there was little change in the overall secondary structure. This is
evident from the far-UV CD absorbance spectra for tGRP1 and tGRP2 shown in
Figures 4.5b and 4.6 a., respectively. There is a slight change in the α-helix peak
(approx. 210 nm and 220 nm) in the spectrum of tGRP1. This may be due to a
small change in the folding of the helices in the vicinity of the truncated portion of
the sequence. However, upon examining the individual spectra of the three data
accumulations for each experiment, the differences may also be attributable to
noise in the data.
The near-UV absorbance spectra (Figures 4.5 and 4.6 b) exhibit a small
amount of change in the tertiary structure in the vicinity of the aromatic amino
acids of the proteins upon glucose binding in the protein tGRP1.

This is

observed in the near-UV CD absorbance spectra shown in Figure 5b.

The

regions of the spectra which exhibit a slight difference correspond to
phenylalanine (250-270) and tryptophan (280-300), while that corresponding to
tyrosine (270-290) appears to remain unchanged. This is consistent with the
known models for the conformational change for native GBP.[161] Examination
of the local environments around these amino acids throughout the
conformational change upon glucose binding gives some insight into the changes
observed in the near-UV CD spectra. In particular, there is both a tryptophan
and a phenylalanine residue present within the binding pocket (Figure 4.7), and
both of these amino acids seem to undergo a change in solvent exposure upon

109

a.

b.

Figure 4.6. Far-UV (a.) and near-UV (b.) CD absorbance of tGRP2 in the
presence and absence of 100 mM glucose.
Protein solutions and corresponding blanks were prepared at a concentration of
0.2 mg/mL in CD buffer in the presence and absence of glucose as described in
Figure 4.3. The CD absorbance was measured from 260-200 nm at a pitch of
0.5 nm in continuous scanning mode at a scan speed of 20 nm/sec for far-UV
and 350-250 nm at a pitch of 0.5 nm and scan speed of 20 nm/min for near-UV
measurements. Three accumulations were averaged for each sample at room
temperature. The response for each blank was subtracted from the response for
the corresponding sample and the resulting spectra are shown.
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Figure 4.7. Modeled structure near the binding pocket in the absence (a.)
and presence (b.) of glucose.

The structures above were modeled using

Discovery Studio 3.0 and coordinates provided in protein data bank (PDB) files
2FW0 and 2FVY, respectively.

The tryptophan near the binding pocket is

colored yellow, and the phenylalanine is colored orange.
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glucose binding.

None of the other aromatic amino acids undergo such a

noticeable change upon ligand binding.

CONCLUSION
In conclusion, we present here a biosensor based upon truncated forms of
GBP from E. coli. Previous work has shown full-length GBP to have a binding
constant in the micromolar range, which is too low for the development of a
glucose biosensing system at physiologically relevant concentrations.

The

apparent binding constant of the truncated proteins is shifted from the micromolar
range, allowing for glucose determination in the physiologically relevant range.
However, truncation of GBP also resulted in a decrease in thermal stability,
decreasing the melting temperature for the protein when compared to its native
form.

Ongoing work in our laboratory aims to modify GBP through the

incorporation of unnatural amino acids, which may further modify properties of
the protein such as the binding constant and thermal stability. Additionally, the
development of glucose recognition proteins based upon template proteins from
thermophillic organisms should also yield more thermostable proteins.

Copyright © Kendrick Bruce Turner 2011
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CHAPTER FIVE
DESIGN AND CHARACTERIZATION OF A GLUCOSE BIOSENSOR BASED
ON THE INTRINSIC FLUORESCENCE OF A TRUNCATED, THERMOSTABLE
GLUCOSE RECOGNITION PEPTIDE

INTRODUCTION
The World Health Organization and others project that by 2050, as many
as one-third of Americans may suffer from diabetes.[162]

Among the

contributing factors to this projection are poor lifestyle habits of the population, an
aging population, and the increasing prevalence of other medical conditions as
risk factors for diabetes. As a result of this worsening epidemic, a need exists for
reliable technologies to monitor the physiological concentration of glucose in
order to effectively manage the disease. Current-generation glucose monitoring
systems rely on electrochemical methods for glucose detection, typically
employing

the

enzyme

glucose

electrochemical sensor.[96, 149]

oxidase

(GOx)

in

a

mediator-based

Many of these devices are commercially

available, both for single-point blood glucose measurement and for continuous
glucose monitoring in interstitial fluid. While they have been very successful
devices, they do suffer from some limitations.

Among these limitations are

interference from other electrochemically active molecules, oxygen-dependence,
and poor performance in the hypoglycemic range.[96, 150]
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As an alternative to electrochemical-based detection methods, various
optical methods have been pursued for the detection of glucose in biological
fluids.[72, 163] Among these are reagentless biosensing systems based on the
binding ability of fluorescently-labeled glucose/galactose binding protein (GBP)
from E. coli to glucose.[89] GBP is a well-characterized protein first identified in
E. coli, which binds glucose in a binding cleft located between two lobes that are
connected by a flexible hinge region consisting of three strands with random coil
secondary structure. This binding results in a significant conformational change
of the overall protein, bringing together the lobes by 8.5 Å.[159] By attaching
environmentally-sensitive fluorophores to the protein, a change in the
fluorescence signal corresponding to the glucose concentration can be observed.
Extensive research in modifying native GBP and site-specifically attaching
various fluorophores to it has resulted in the development of proteins capable of
sensitive, reproducible detection of glucose at concentrations approaching those
in the physiological range.[151, 153]
While work in the development of these fluorescent glucose biosensing
systems has been ongoing for many years, no commercially-available sensing
device has yet been developed.

One factor limiting the development of a

fluorescence-based glucose-sensing device is that the labeled GBP needs to
remain stable for extended periods of time. To that end, the identification of
GBPs from thermophilic organisms such as Pyrococcus horikoshii[164], Thermus
thermophilus[165], and Thermotoga maritima[166] has opened new avenues for
the development of more rugged, long-lived biosensing systems for glucose.
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Proteins isolated from thermophilic organisms are remarkably stable with respect
to extreme temperature, ionic strength, pH, and presence of chaotropic
chemicals making them ideal for the development of biosensing systems that
must be able to detect their target analyte in a sensitive and reproducible manner
over long periods of time.[167]
In this work, we report the design and characterization of a glucose
recognition peptide, tmGRP4, based upon a truncated form of the glucose
binding protein (tmGBP) from the microorganism Thermotoga maritima (Figure
5.1).

Previously, it has been shown that full-length tmGRP site-specifically

labeled at various locations with a fluorophore is capable of detecting glucose
with binding affinities ranging from 12.7 nM to 147.7 mM.[166]

By studying

truncated portions of the protein, we hypothesize that we can gain insights into
the activity of the protein and identify portions that are required for ligand binding.
This information will contribute to the further improvement and customization of
the protein and the development of a minimized protein structure. Herein, we
demonstrate the feasibility of using the intrinsic fluorescence of a truncated form
of the protein resulting from a single tryptophan residue present in the protein’s
binding pocket as a means of detecting and quantifying glucose, thus eliminating
the need for separate protein modification steps.

Additionally, by monitoring

changes in intrinsic fluorescence, we have been able to characterize the protein
with respect to binding affinity and selectivity without perturbations in its
structure, a potential drawback when proteins are modified with a fluorophore in
a location near the binding pocket.
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EXPERIMENTAL PROCEDURES
Reagents.

Oligonucleotide

Biotechnologies (Huntsville, AL).

primers

were

purchased

from

Operon

Thermotoga maritima genomic DNA was

purchased from ATCC (Manassas, VA). Ampicillin, chloramphenicol, glucose,
sodium ascorbate, D(+)-raffinose, cholesterol, D-Lyxose, L(+)-arabinose, D(+)maltose, lactose, 2-amino-2-hydroxymethyl-propane-1,3-diol (tris base), βmercaptoethanol, and agarose were purchased from Sigma (St. Louis, MO).
Luria-Bertani (LB) broth and agar, sodium chloride, sucrose, sodium phosphate
monobasic, sodium phosphate dibasic and glycine were purchased from Fisher
Scientific (Fair Lawn, NJ). Restriction enzymes XhoI and BamHI and T4 DNA
ligase were purchased from Promega (Madison, WI). Ni-NTA agarose resin,
QIAquick gel purification kit, and QIAprep DNA isolation kit were purchased from
Qiagen (Valencia, CA).

QuickChange II site-directed mutagenesis kit and

pfuUltraII DNA polymerase were purchased from Stratagene (La Jolla, CA).
Imidazole and guanidine hydrochloride were purchased from J.T. Baker
(Phillipsburg, NJ). D(+)-galactose was purchased from Acros Organics (Geel,
Belgium). Sodium dodecyl sulfate (SDS) was purchased from Curtin Matheson
(Houston, TX). Tris(2-carboxyethyl)phosphine (TCEP) and Rosetta 2 (DE3) cells
were

purchased

from

EMD

(Gibbstown,

NJ).

Isopropyl

β-D-1-

thiogalactopyranoside (IPTG) was purchased from Gold Biotechnology (St.
Louis, MO). TOP10F’ cells were purchased from Invitrogen (Carlsbad, CA). The
vector pET21a(+) was purchased from Novagen (Darmstadt, Germany). D(+)fructose was purchased from Spectrum (Gardena, CA).
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Apparatus.
Eppendorf

Polymerase chain reactions (PCR) were performed using an
Mastercycler

Personal

Thermocycler

(Hauppauge,

NY).

Electrophoresis of DNA was carried out using an FB105 Fischer Biotech
Electrophoresis Power Supply (Pittsburg, PA). DNA gels were visualized using a
UV Transilluminator platform from UVP (Upland, CA).

Optical density

measurements were taken using a Spectronic 21D from Milton Roy (Ivy Land,
PA). Cells were lysed using a 550 Sonic Dismembrator from Fisher Scientific
(Pittsburg, PA). Cell cultures were grown by incubating bacteria in a Forma
Scientific Orbital Shaker (Fairlawn, NJ).

All centrifugations were carried out

using a Beckman J2MI centrifuge (Palo Alto, CA). Proteins were visualized by
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using
Mini-PROTEAN TGX 4-20% SDS-PAGE gels purchased from Bio-Rad
(Hercules, CA).

Fluorescence measurements were obtained using a

QuantaMaster 40 Spectrofluorometer from PTI (Birmingham, NJ).

Circular

dichroism experiments were performed using a BioLogic MOS 450/PMS 450
Spectrometer from BioLogic (Claix, France).
Cloning of Glucose Recognition Peptides (tGRPs) into Expression Plasmid.
The gene for GBP from T. maritima was isolated by PCR from purchased
genomic

DNA

using

the

primers

tmGRP-21aXhoI

(5’-

GGTGGTCTCGAGGAATTTTATTGGAATTCCG-3’) and tmGRP-21aBamHI (5’GGTGGTGGATCCCTCACCATAGGTGTTATCGG-3’) with the restriction sites
XhoI and BamHI underlined, respectively. The PCR reaction was carried out
using pfuUltraII DNA polymerase with an initial denaturation of 95 °C for 2 min.
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Next, 30 cycles of a denaturation step at 95 °C for 30 s, and annealing step at 63
°C for 20 s, and an elongation step at 72 °C for 30 s were carried out. A final
elongation step of 72 °C for 3 min completed the PCR reaction. The resulting
products were analyzed by agarose gel electrophoresis for correct size and
purity, and the appropriately sized band (915 bp) was excised from the gel and
purified using the QIAquick gel extraction kit.
Following PCR product purification, the product along with the expression
vector pET21a(+) were digested with restriction enzymes XhoI and BamHI.
Digestion was carried out per instructions provided with the restriction enzymes.
Following digestion, the products were analyzed by agarose gel electrophoresis.
Next, a gel slice of digested PCR product was combined with a gel slice of
digested expression vector and co-purified using the QIAquick gel extraction kit.
To the purified DNA, T4 ligase and T4 ligase buffer (10x) were added, and the
ligation reaction was allowed to complete overnight at room temperature. The
resulting ligated DNA was transformed into TOP10F’ cells following standard
transformation procedures.

Colonies resulting from the transformation were

analyzed for the presence of the correct insert by overnight growth in LB media
supplemented with ampicillin (100 µg/mL) and digestion of the purified DNA with
restriction enzymes XhoI and BamHI as above. Glycerol stocks were made of
those colonies which appeared correct, and the isolated plasmid, tmGRPpET21a(+), was sent for DNA sequencing for confirmation.
In order to introduce a cysteine at position 135, site-directed mutagenesis
was carried out using the QuickChange II site-directed mutagenesis kit. The
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mutagenesis

primers

used

were

tmGRP-mut-135A/C

(5’-

ACGGGTTCACTGACATGTATGAACTCCCTTCAG-3’) and tmGRP-135A/C-rev
(5’-CTGAAGGGAGTTCATACATGTCAGTGAACCCGA-3’). The reaction mixture
was prepared per the kit instructions. An initial denaturation step was performed
at 95 °C for 30 s. Following this, 30 cycles of a denaturation step at 95 °C for 30
s, an annealing step of 55 °C for 1 min, and an elongation step of 68 °C for 5 min
were completed. A final elongation step was performed at 68 °C for 5 min. The
resulting products were analyzed for purity and correct size by agarose gel
electrophoresis. The resulting mutated plasmid was transformed into TOP10F’
cells following standard transformation protocols. Following the transformation,
colonies were analyzed for the presence of the correct plasmid by growth
overnight in LB broth supplemented with ampicillin (100 µg/mL).

From the

overnight cultures, the plasmid DNA was isolated and digested as above with
XhoI and BamHI and analyzed by agarose gel electrophoresis to confirm the
presence of the insert and expression vector bands.

Glycerol stocks were

prepared of appropriate colonies, and the isolated plasmid, tmGRP135CpET21a(+), was sent for DNA sequencing for confirmation.
For the preparation of truncated glucose binding proteins from T. maritima
(tmGRP4), PCR was performed using the above prepared plasmid, tmGRP135CpET21a(+), as template DNA. The final truncated proteins were designed to
consist of amino acids 14-254 (tGRP4), 14-206 (tGRP5) and 1-254 (tGRP6) of
the native protein.
tmGRP135

gene

A PCR reaction was carried out for truncation of the
using

the

primers
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tmGRP4-fwd-BamHI

(5’-

GGTGGTGGATCCTACTGGTCACAGGTAGAACAAGGT-3’) and tmGRP4-revXhoI

(5’-GGTGGTCTCGAGCTTGTTCATCAGATAAAGAACTGT-3’)

for

the

amplification of tGRP4, the primers tmGRP4-fwd-BamHI and tmGRP5-rev-XhoI
(5’-GGTGGTCTCGAGTTTTCCAGCATTTTTCACCACGAG-3’)
amplification

of

tGRP5,

and

the

primers

for

tmGRP6-fwd-BamHI

GGTGGTGGATCCCTCCACCATAGGTGTTATCGGAAAA-3’)

and

the
(5’-

tGRP4-rev-

XhoI for the amplification of tGRP6. PCR reaction parameters were identical as
above for the preparation of tmGRP-pET21a(+). Following the PCR reaction, the
products were analyzed by agarose gel electrophoresis. DNA bands for tGRP4
(723 bp), tGRP5 (579 bp), and tGRP6 (759 bp) were excised and purified using
the QIAquick kit. After DNA isolation, each product, along with expression vector
pET21a(+) were digested with restriction enzymes XhoI and BamHI as above.
The digested DNA was purified by agarose gel electrophoresis, and the
appropriate DNA bands were excised from the gel. In separate tubes, excised
DNA of each truncated product was combined with excised DNA for the
expression vector, and co-purified using the QIAquick kit. To the purified DNA,
T4 DNA ligase and T4 ligase buffer (10x) were added, and the ligation reaction
was incubated overnight at room temperature.

After ligation, the resulting

plasmids, tGRP4-pET21a(+), tGRP5-pET21a(+), and tGRP6-pET21a(+) were
transformed into Rosetta2(DE3) cells for protein expression.

Colonies from

these transformations were grown overnight in LB broth supplemented with
ampicillin (100 µg/mL) and chloramphenicol (25 µg/mL), preserved as glycerol
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stocks, and plasmid DNA was isolated as before and sent for sequencing for
confirmation.
Recombinant Protein Expression and Purification.

For the expression of

tGRP4, an overnight culture of tGRP4-pET21a(+) in Rosetta2(DE3) was grown in
LB media supplemented with ampicillin (100 µg/mL) and chloramphenicol (25
µg/mL). The following day, expression cultures were grown (2 x 500 mL) in LB
broth supplemented with ampicillin (100 µg/mL) and chloramphenicol (25 µg/mL)
at 37 °C to an OD600 of approximately 0.5. Protein expression was induced by
the addition of IPTG to a final concentration of 1.0 mM, and the culture was
grown overnight at 37 °C.
In order to harvest the cells after protein expression, the culture was
centrifuged at 12,000 x g, at 4 °C, for 20 min. Cells were resuspended in lysis
buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0) and lysed by
pulsed sonication (10 s on, 10 s off, 10 min total sonication). Following cell lysis,
the lysate was centrifuged at 12,000 x g, at 4 °C, for 20 min, to remove debris.
The supernatant was transferred to a fresh centrifuge tube, 1.0 mL of Ni-NTA
agarose resin was added, and the solution was incubated at 4 °C for 1 h. The
solution was then applied to a gravity-flow column, and the flow-through fraction
was collected. The resin was then washed with 10 mL of wash buffer 1 (50 mM
NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0), then 3 mL of wash buffer 2
(50 mM NaH2PO4, 300 mM NaCl, 50 mM imidazole, pH 8.0), and finally 3 mL of
wash buffer 3 (50 mM NaH2PO4, 300 mM NaCl, 100 mM imidazole, pH 8.0). The
wash fractions were collected in separate tubes. Finally, the protein was eluted
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from the column in six 1.0 mL fractions of elution buffer (50 mM NaH2PO4, 300
mM NaCl, 250 mM imidazole, pH 8.0). Following purification, the products were
analyzed for purity by SDS-PAGE. Elution fractions containing purified protein
were combined in an amber glass vial and stored at 4 °C. Protein concentrations
were determined using method A detailed by Greenfield et al.[156]
Fluorescence Measurements of GRPs. All fluorescence measurements were
carried out in assay buffer (20 mM phosphate, 20 mM NaCl, 1.0 mM TCEP, pH
7.0) at a protein concentration of 1.0 x 10-6 M. Glucose standards were prepared
in assay buffer and stored at 4 °C. Tryptophan fluorescence was excited at 278
nm and emission was measured at 340 nm. For excitation and emission scans,
instrument settings were as follows: excitation and emission slit widths were set
at 1 nm and 3 nm respectively, monochromator step size was set at 0.5 nm,
integration time was 0.5 s, 3 scans were averaged for each acquisition. For
glucose assays, a time-based acquisition program was established with the
same excitation and emission wavelengths as above, and fluorescence intensity
was averaged over 2.5 s with a single reading every 0.5 s. Apparent binding
constants were determined using the statistical analysis software GraphPad 5.0.
Briefly, the fluorescence intensity was plotted versus glucose concentration and a
sigmoidal response curve was fitted to the data following Equation 1:
Equation 1
In Equation 1, the values for Top and Bottom are determined by the plateau
regions resulting from the highest and lowest concentration data points,
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respectively. The Hill slope is variable and dependent upon the slope along the
curve calculated about each data point. The logEC50 is the logarithm of the
concentration that results in a change in signal halfway between the Top and
Bottom values, or when half of the protein binding sites are occupied. For this
reason, the apparent binding constant can be derived from the logEC50 value.
Determination of Protein Thermal Stability.

Protein thermal stability was

investigated by the measurement in intrinsic tryptophan fluorescence as a
function of temperature and the concentration of the chaotropic agent guanidine
hydrochloride.
experiment.

Briefly, the same protein concentration was used for each
The instrument settings were also kept the same as described

above. Fluorescence was measured at the wavelengths used above throughout
a temperature ramp from 20 °C to 90 °C at a rate of 5 °C per minute with stirring.
An initial hold time of 180 s at 20 °C was used prior to the temperature ramp, and
the linear decay of fluorescence was extrapolated throughout the total
experiment time and subtracted from the temperature ramp fluorescence curve in
order to account for the effects of photobleaching throughout the experiment.
Samples were measured both in the absence of glucose, and with a glucose
concentration of 1.0 M.

Additionally, the concentration of guanidine

hydrochloride was varied from 0.0 M to 4.5 M.
Measurement of Far- and Near-UV Circular Dichroism (CD) Spectra.

To

investigate protein conformational changes upon glucose binding, both far- and
near-UV circular dichroism spectra were measured. For far-UV CD, the proteins
were evaluated at a concentration of 0.2 mg/mL in CD buffer (20 mM phosphate,
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20 mM NaCl, pH 7.0) in a quartz cuvette with a pathlength of 1.0 mm. Instrument
settings were as follows: wavelength range was 180-260 nm, scan repeat was 4,
acquisition duration was 20 s, and shutter mode was always open. Samples
were measured in the absence of glucose, and with a glucose concentration of
100 mM.

Corresponding blanks were measured with the same glucose

concentrations in buffer, with no protein present, and subtracted from the protein
CD data. For near-UV CD, the proteins were evaluated at a concentration of 1.0
mg/mL in CD buffer in a quartz cuvette with a pathlength of 1.0 cm. Instrument
settings and sample preparation were as above for far-UV CD, except the
wavelength range was 250-350 nm.
Determination of Protein Specificity. Protein specificity was determined for
selected analytes. Sample solutions of protein in assay buffer were prepared in
a similar manner as for glucose assays. To these protein solutions, the selected
analytes were added, in triplicate, and the fluorescence intensity was measured.
Analytes were added to the protein solution at a final concentration of 1.0 mM
with the exception of cholesterol, and ascorbate, which were added at a final
concentration of 10 and 50 µM, respectively.

RESULTS AND DISCUSSION
In this work, we report the design of a truncated form of the glucose
binding protein from Thermotoga maritima. By studying truncated versions of the
full-length protein, we have gained some insight into portions of the protein which
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are necessary for proper folding and activity. Specifically, it was observed that
tGRP5, which lacks 113 out of 305 amino acids of full-length tmGRP was unable
to properly fold and/or respond to glucose (data not shown). However tGRP4,
which lacks 65 amino acids, maintains a response to glucose. This suggests that
some of the amino acids removed in tGRP5 must be essential for protein folding
and glucose interaction. Previously published strategies for engineering glucose
binding proteins to elicit an optical response have relied on fusion with a suitable
bioluminescent or fluorescent reporter protein[72, 168] or the site-specific
incorporation of a cysteine residue and subsequent covalent attachment of
environmentally-sensitive organic fluorophores.[89, 151]

The engineered

protein in this work, tGRP4, contains a single tryptophan residue that resides in
the binding cavity of the protein and interacts directly with glucose through a
hydrogen bonding interaction (figure 5.1). When tGRP4 is bound to glucose, this
tryptophan

shows

a

concentration-dependent

enhancement

of

intrinsic

tryptophan fluorescence resulting in a total fluorescence enhancement of
approximately 9% at maximum signal intensity and an apparent binding constant
of 3.0 x 10-6 (figure 5.2). Continuous, time-based measurements of tGRP4 in
solution also showed that the total change in fluorescence is observed within 5 s
of the addition of glucose (data not shown).
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Figure 5.2. Calibration curve of tGRP4 in response to glucose. The percent
enhancement of the intrinsic tryptophan fluorescence intensity with respect to
glucose concentration is shown above. tGRP4 was added to 2.0 mL of assay
buffer at a final concentration of 1.0 x 10-6 M in a quartz cuvette with a path
length of 1 cm. Glucose was added from standard solutions in aliquots of 0.5 µM
resulting in the final concentrations above.

Data represent an average of 3

replicate measurements with standard deviations depicted with error bars (some
error bars obscured by datap points.

A sigmoidal-response curve was fitted

using GraphPad Prism 5.0 software, and an apparent binding constant of 3.0 x
10-6 M was calculated based on the curve.
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Previously developed biosensors based on GBP from E. coli have been
shown to respond to galactose as well as glucose with a slightly higher binding
affinity latter.[89] Work in our laboratory has demonstrated that truncating the
native protein structure for GBP from E. coli alters the binding affinity and
response of the protein.

To investigate whether the selectivity of tGRP4 is

altered compared to full-length tmGBP, we measured the response of the protein
to several other sugars as well as cholesterol and ascorbate, which have been
shown to act as interfering species in electrochemically-based glucose sensors.
The compounds were investigated at the following concentrations: ascorbate
was added at a concentration of 50 µM, cholesterol was added at a concentration
of 10 µM, and all sugars were added at a concentration of 1 mM. As shown in
figure 5.3, the addition of maltose, a disaccharide of glucose, results in an
enhancement of fluorescence that is indistinguishable from glucose. However,
physiologically, maltose is rapidly metabolized to glucose. Additionally, there is a
significant quenching in fluorescence resulting from the addition of ascorbate.
This quenching effect is also observed in solutions of tryptophan (data not
shown) indicating that the effect is not due to the binding of ascorbate to the
protein, but rather to quenching of tryptophan fluorescence by ascorbic acid.
To investigate this effect, we performed experiments to determine the
effects of various physiologically-relevant concentrations of ascorbic acid on the
response of the protein (Figure 5.4). Indeed, as the concentration of ascorbic
acid was increased, the raw fluorescence measured decreased. However, it was
observed that the addition of glucose still resulted in fluorescence enhancement,
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Figure 5.3. Selectivity study of tGRP4. Each compound was added at a final
concentration of 1.0 mM in triplicate, except ascorbate which was added at 50
µM and cholesterol, which was added at 10 µM. The response of maltose was
indistinguishable from that of glucose, and ascorbate demonstrated a dramatic
quenching effect of tryptophan fluorescence at the concentration above.
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Figure 5.4.

Glucose calibration curves in the presence of ascorbate.

Glucose assays were performed at 0 µM (▼), 10 µM (●), and 100 µM (■) of
ascorbate.

While the percent enhancement of tryptophan fluorescence was

maintained, the raw signal was decreased as the concentration of ascorbate was
increased.

Data represent an average of 3 replicate measurements with

standard deviations depicted with error bars (some error bars obscured by data
points).

A sigmoidal-response curve was fitted using GraphPad Prism 5.0

software,
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and the percent enhancement of fluorescence was virtually identical to that
observed in the absence of ascorbic acid. Because of this, it is believed that a
biosensing system which employs the intrinsic fluorescence of tGRP4 would still
be feasible if a standard addition approach was used to eliminate the interference
from ascorbic acid.
In the development of a commercially-viable device, an important
parameter for any blood glucose monitoring system is sensor lifetime, especially
for continuous glucose monitors (CGMs). Sensor lifetimes are limited by several
factors, most prominently an immune response to the implanted sensor as a
foreign body.[169] There are only a few FDA-approved CGMs currently on the
market, and most of these have sensor lifetimes of 3-5 days, with the longest
being 7 days. To test the lifetime of tGRP4, we compared the response of fresh
protein from storage at 4 °C to that of protein stored long-term at 37 °C. The
results of this study, shown in figure 5.5, reveal that virtually no loss in tGRP4
activity is observed within 72 h. The protein is still capable of glucose detection
for as long as 5 days, albeit at a decreased response.
To further investigate the thermal stability of tGRP4, glucose assays were
carried out at temperatures ranging from 37 °C to 60 °C (Figure 5.6).

The

importance of protein stability to high temperatures related not just to
physiological measurements, but also to transport and storage of proteins that
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Figure 5.5. Effect of long-term storage at 37 °C on assay performance.
Glucose assays were completed with protein solution fresh from storage at 4 ºC
(●), and after protein storage at 37 °C for 24 h (■), 48 h (▲), 72 h (■), 96 h (▼),
120 h (♦), and 168 h (+). Protein activity was maintained through 72 h, at which
time the percent fluorescence enhancement began to decrease. No glucose
response was observed beyond 120 h. Data represent an average of 3 replicate
measurements with standard deviations depicted with error bars (some error
bars may be obscured by data points). A sigmoidal-response curve was fitted
using GraphPad Prism 5.0 software,
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Figure 5.6. Effect of temperature on glucose response. Glucose assays were
performed at 37 ºC (●), 44 ºC (■), 50 ºC (▼), and 60 ºC (♦). Data represent an
average of 3 replicate measurements with standard deviations depicted with
error bars (some error bars may be obscured by data points). A sigmoidalresponse curve was fitted using GraphPad Prism 5.0 software.
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need to be used in devices and as diagnostic tools. Proteins with improved
thermal stability tend to have increased tolerance to elevated temperatures
during measurement and improved shelf-life at non-ideal storage and transport
conditions (i.e., tropical or desert environments).

This improved tolerance

reduces the need for special storage conditions, making devices based upon
these proteins more amenable to use in extreme environments. As expected for
a thermostable protein, activity was maintained at higher temperatures. As the
temperature was increased further to 60 °C, the response curve was shifted to an
increased apparent binding affinity of 2.6 x 10-4 M. For a thermostable protein, it
would be expected that binding would be stronger at a higher temperature. This
observed shift in binding affinity is likely the result of a decreased rigidity in the
protein structure of the truncated protein as compared to the full-length protein.
As the overall flexibility of the protein structure is increased, the binding of
glucose within the binding cavity likely becomes less favorable.

As the

temperature increased, a decrease in absolute fluorescence intensity was also
observed. This can likely be attributed to increased collisional quenching as the
flexibility of the protein is increased and the exposure of tryptophan to the solvent
increases.
The stability of the protein structure was further explored by measuring the
fluorescence intensity of the tryptophan residue as the temperature was
increased from room temperature to 90 °C in the presence of the chaotropic
agent, guanidine hydrochloride.

Guanidine was added to shift the melting

transition of the protein to a temperature that is experimentally relevant, since the
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protein in the absence of chaotropic agents has a melting temperature well
above the boiling point of water. As mentioned above, tGRP4 contains a single
tryptophan residue located within the binding cavity, in the hydrophobic interior of
the protein. As chemical and thermal stresses are placed on the protein, its
secondary and tertiary structural features should begin to unravel as the protein
denatures. This should result in the buried tryptophan residue becoming more
exposed to the aqueous environment surrounding the protein, and a decrease in
measured intrinsic tryptophan fluorescence. It has also been previously shown
that the presence of glucose contributes to an increased stability of the protein
structure of GBPs, resulting in an increase in thermal- and chemicalstability.[160, 166] Figure 5.7 shows the normalized tryptophan fluorescence as
a function of temperature with various concentrations of guanidine present. As
shown in figure 5.7a, the melting transition is observed to begin around 70 °C in
the absence of glucose and around 80 °C in the presence of glucose at a
guanidine concentration of 1.0 M, and the protein never reaches a completely
unfolded state, as indicated by the continuous decrease in fluorescence. At 3.0
M guanidine (figure 5.7b), the protein begins to unfold at a temperature just
above 40 °C in the absence of glucose, and begins to reach a completely
unfolded state at around 70 °C. In the presence of glucose, protein structure is
maintained and the melting transition is again observed to begin at approximately
80 °C. Finally, at a concentration of 4.5 M guanidine (figure 5.7c) and in the
absence of glucose, the melting transition begins just above 20 °C, indicating a
highly denaturing environment, however, denaturation is still incomplete until a
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a.

b.

c.
Figure 5.7. Thermal and chemical denaturation of tGRP4. Assay solutions
were prepared in the absence and presence of glucose with various
concentrations of guanidine hydrochloride (Guan). While measuring tryptophan
fluorescence, the temperature was ramped from 20-90 °C. Protein melting was
observed as the tryptophan fluorescence is quenched. As the concentration of
guanidine was increased, the melting transition shifted to lower temperatures. As
shown by the increased melting transition temperatures, the presence of glucose
increased the stability of the protein structure.

136

temperature of approximately 75 °C. In the presence of glucose at this guanidine
concentration, denaturation does not begin until approximately 60 °C, and the
protein is not completely disordered until over 80 °C.
In order to investigate the conformational change which occurs in tGRP4
upon glucose binding, the far- and near-UV CD spectra were measured in the
absence and presence of glucose.

As shown in figure 5.8a, the far-UV CD

spectrum, which reveals changes in protein secondary structure, showed little
change in response to glucose. This is consistent with available structural data
for full-length tmGBP. Near-UV spectra, on the other hand, provides information
on changes in the tertiary structure in the environment around the aromatic
amino acids phenylalanine (250-270 nm), tyrosine (270-290 nm), and tryptophan
(280-300 nm). As shown in figure 5.8b, there is a broad peak centered around
275 nm that is somewhat increased in the presence of glucose. This is likely
attributed to a tyrosine located on the edge of the binding pocket that is believed
to experience a change in solvent exposure as a result of the conformational
change.

CONCLUSION
In this work, we have developed a glucose biosensor using a thermally
stable protein, tGRP4, which is based on a truncated form of GBP from the
hyperthermophilic organism, Thermotoga maritima. Many previous glucose
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a.

b.
Figure 5.8. Far-UV (a.) and near-UV (b.)CD absorbance of tGRP4 in the
presence and absence of 100 mM glucose.

Protein solutions and

corresponding blanks were prepared at a concentration of 0.2 mg/mL in CD
buffer containing 0 mM (---) or 100 mM (—) glucose as described in figure 5.3.
The CD absorbance was measured from 200-260 nm for far-UV and 250-350 nm
for near-UV measurements. Four accumulations were averaged for each sample
at room temperature. The response for each blank was subtracted from the
response for the corresponding sample and the resulting spectra are shown.
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biosensing systems based on glucose binding proteins rely on the covalent
attachment of a small fluorophore to a specific position within the protein
structure. The work presented herein instead relies on the intrinsic fluorescence
of a tryptophan residue located within the binding cavity of the protein, negating
the time and expense of the extra labeling steps required for fluorophore-labeled
proteins.

This approach could be applied to other protein-based sensing

systems through the introduction of a unique tryptophan within a protein’s
structure. We have shown that tmGRP can withstand the removal of 65 amino
acids (over 20% of the total protein) while still maintaining binding activity. This
provides insight into developing a minimized protein structure, which may be
more amenable to customizability. We have also demonstrated several desirable
properties of a CGM system such as a sensor lifetime on the order of 3-5 days,
maintained sensor performance under extreme conditions, and accurate
detection of glucose which was both reproducible, and selective. The improved
thermal stability gained from using a hyperthermophilic variant of GBP provides
the advantages of a rugged protein that is more tolerable of extreme conditions
such as temperature both during use in a biosensing system as well as during
storage and transport. We envision that integration of the engineered protein into
a fiber-optic based biosensing system will result in the design and development
of long-lived practical optical glucose monitoring platforms and devices capable
of performance at physiological temperatures and pH, and that are selective to
glucose over a wide variety of sugars.
Copyright © Kendrick Bruce Turner 2011
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CHAPTER SIX

CONCLUSIONS AND FUTURE PERSPECTIVES

Nature has spent billions of years evolving mechanisms by which
organisms can sense and respond selectively to stimuli in their surrounding
environment. This degree of adaptation has allowed organisms to identify and
transport needed nutrients into cells, to remove waste products that would
otherwise accumulate to toxic concentrations within cells, and to defend against
exposure to harmful toxicants.

The biological sensing tools that nature has

developed to accomplish these tasks have been discussed extensively in this
dissertation and include regulatory proteins that recognize small effector
molecules and trigger the expression of appropriate genes and chemotaxis
proteins that actively transport small molecules into and out of cells. It has been
the goal of this work to exploit these naturally occurring biosensing systems and
engineer them to serve as sensitive, selective, reproducible, and rugged systems
which can be employed in the detection of small molecules of interest, including
both biologically and physiologically relevant compounds. Additionally, we have
gained some insight into the relationship between the structure of the various
sensing proteins studied and their relevant analytical response characteristics.
Chapter two presented a whole cell sensing system for hydroxylated
polychlorinated biphenyls (OH-PCBs).

These compounds are metabolites of

PCBs and can serve as a biomarker of PCB exposure.
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By employing the

regulatory protein, HbpR, from the bacterium Pseudomonas azelaica, we were
able to construct a biosensing system capable of detection OH-PCBs at
concentrations down to the nanomolar range. In this strategy, the expression of
the reporter protein, bacterial luciferase, was put under the regulatory control of
HbpR.

Chapter three presents a protein-based sensing system based upon

HbpR.

In this work, the effector binding A-domain of HbpR (HbpR-A) was

isolated and labeled at cysteines in the structure with an environmentallysensitive

fluorophore,

5-[2-[(2-Iodo-1-oxoethyl)amino]ethylamino]-1-

naphthalenesulfonic acid (IAEDANS).

Upon analyte binding, likely due to a

conformational change in HbpR-A, a change in the fluorescence intensity
observed that could be correlated to OH-PCB concentration. A limiting factor in
the development of the protein-based biosensor was the lack of structural
information available for HbpR. Serendipitously, our protein was responsive to
OH-PCBs when labeled with IAEDANS. Determination of the three-dimensional
structure of HbpR would allow a more rational approach to improving the
response of the sensing system. For instance, by replacing or removing any
cysteines which are not affected by the conformational change, the background
fluorescence could be reduced, which should result in improved detection limits.
Additionally, identification of amino acids present in the binding pocket of the
protein and elucidation of the specific interactions between these amino acids
and the OH-PCBS should provide the opportunity to rationally alter these
interactions to improve the selectivity of the protein which could eventually allow
us to tailor the protein such that we can preferentially detect some OH-PCBs
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(e.g., more highly-substituted congeners) over others. Ongoing work by groups
with greater expertise in protein structure determinations, especially the van der
Meer group, is attempting to determine a structure for HbpR. However, this class
of regulatory proteins has presented much difficulty in expression and purification
of isolated, full-length protein.

This has hindered the determination of the

structure of HbpR.
In chapter four, truncated fragments of the extensively studied glucose
binding protein (GBP) from E. coli were engineered to function as a biosensor for
glucose. Native GBP has been previously engineered such that a fluorophore, 7diethylamino-3-((((2-maleimidyl)ethyl)amino)carbonyl)coumarin

(MDCC),

was

attached at a unique cysteine at position 152. However, the full-length native
protein has been found to have a binding affinity in the micromolar range. In
order to be useful in a sensing system for physiologically-relevant glucose
concentrations, the binding affinity would need to be in the millimolar range. To
that end, we designed truncated glucose recognition peptides (tGRPs) based
upon the template of full-length GBP. We hypothesized that by truncating the
native protein, we may be able to see a shift in the binding affinity, in addition to
other changes in the characteristics of the protein. Indeed, we observed that as
the protein was truncated to a greater extent, the binding affinity shifted to higher
concentrations of glucose.

However, truncating the native protein also

demonstrated the negative effect of reducing the thermal stability of the protein,
resulting in a melting temperature much lower than full-length GBP. Preliminary
work in our laboratory has circumvented this through the global incorporation of
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fluorinated unnatural amino acid analogues that are known to increase the
thermal stability in other proteins.

Additionally, by identifying portions of the

protein that must be conserved to maintain a functional protein, we are moving
toward a small enough protein that the possibility of constructing the protein
using peptide synthesis methods may become a reality. This would allow us
greater control over customizing the protein by easily introducing site-specific
mutations.

Additionally, the library of unnatural amino acids available for

incorporation into the amino acid sequence is more extensive when using solid
state protein synthesis.
The fifth chapter details the pursuit of another protein-based biosensor for
glucose based upon the hyperthermophilic glucose binding protein (tmGBP) from
the extremophil, Thermotoga maritima. We chose this protein because of its
exceptional thermal stability; in the presence of glucose the melting temperature
of tmGBP is well over 100 °C. Improved thermal stability should improve sensor
lifetime and facilitate a more rugged sensor, which can perform in more extreme
conditions and withstand a greater variety of storage and transport conditions.
Again, in this work, we sought to develop truncated fragments of the full-length
protein in an effort to realize a minimized protein structure that would afford all of
the benefits mentioned previously.

This work also relied on the intrinsic

fluorescence of a single tryptophan residue located within the binding pocket of
the protein instead of an exogenous fluorophore. The use of intrinsic protein
fluorescence mitigates the need for extra labeling and purification steps.
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Future work for each of the protein-based sensing systems will also
involve further alteration of the protein structures and, as a consequence, their
response properties by incorporation of unnatural amino acid analogues. This
work is already ongoing in our laboratory with the incorporation of fluorinated
tryptophans and leucines into GBP and the tGRPs discussed in chapter 4.
Results thus far suggest that incorporating these fluorinated amino acids,
especially the fluorinated leucine, increases the thermal stability of the protein.
Other avenues of continued research in this vein include the incorporation of
unnatural amino acids which can themselves be used as the reporter thus
negating the need for an extra fluorophore labeling step. For example, we are
pursuing

the

incorporation

of

electroactive

amino

acids,

such

as

benzoylphenylalanine in an effort to yield a protein which would elicit an
electrochemical response upon glucose binding. The palette of unnatural amino
acids which can be incorporated during in vivo expression is somewhat limited
based on the availability of auxotrophic strains and orthogonal tRNA/synthetase
pairs. Part of the motivation for truncating the proteins in the development of our
sensing systems is the elucidation of minimized protein structures and
identification of essential sequences necessary for protein function.

The

identification of shorter amino acid sequence capable of functioning as a sensor
for a desired analyte will allow for the possibility of solid phase peptide synthesis
which greatly increases the variety of unnatural amino acids which can be
employed.
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A final near-term pursuit of these biosensing systems will entail the
incorporation into devices. Some work in this direction has been pursued by our
laboratory with the incorporation of protein based biosensors for glucose into
fiber-optic based devices.

Preliminary work has been accomplished that

demonstrates the proteins can be incorporated and maintain their binding and
sensing activities.

Future pursuits should include detailed characterization of

these devices with regards to their analytical properties such as sensitivity,
selectivity, reproducibility, and lifetime. Also, validation of the response of the
device with real samples will need to be performed.

In addition, physical

characteristics such as device storage, ruggedness, and transport will need to be
studied.

Finally, the effects and mitigation of an immune response to an

implanted fiber optic sensor will need to be investigated.

Copyright © Kendrick Bruce Turner 2011
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